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ABSTRACT 
 The aim of my thesis is to further investigate the mechanisms underlying 
inflammatory muscle pain. Despite numerous studies investigating the mechanisms of 
inflammatory hyperalgesia, little is known of the mechanisms underlying inflammatory 
muscle hyperalgesia. Using rats as experimental animals, I investigated inflammatory 
hyperalgesia in muscle and compared it to that of inflamed cutaneous tissue. I injected 
carrageenan, a plant-origin polysaccharide, into leg muscle and into the hind paw of 
rats, and measured the behavioural response, as well as cytokine changes, in both 
plasma and inflamed tissue. Carrageenan induced inflammatory hyperalgesia but the 
cytokine cascade was not the same in muscle and cutaneous tissue. At no time 
following carrageenan injection was muscle tumour necrosis factor alpha (TNF-α) 
concentration elevated above that of muscle injected with saline. TNF-α is a key 
inflammatory mediator in cutaneous tissue, but apparently not in muscle. Interleukin-
1β (IL-1β) and interleukin-6 concentrations also were different during muscle 
inflammation compared to those of cutaneous inflammation. IL-1β and IL-6 
concentrations, following carrageenan injection, were elevated later in muscle 
compared to in cutaneous tissue.  IL-1β is a potent sensitizer of nociceptors in 
cutaneous tissue, and also may play an important role in sustaining muscle pain, but it 
is unlikely to be an initiator of the inflammatory muscle hyperalgesia. In the course of 
comparing muscle hyperalgesia and cutaneous hyperalgesia, I aimed to identify whether 
these differences in cytokine concentrations were unique to muscle tissue or if similar 
differences in cytokine concentrations existed between the hind paw and other 
cutaneous sites. To explore an alternative cutaneous tissue site, I injected carrageenan 
into the rat tail and measured the behavioural response, changes in cytokine 
concentrations and histological changes. Elevations of pro-inflammatory cytokines 
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occurred concurrently with the infiltration of leukocytes into the inflamed tail tissue 
with the thermal and mechanical hyperalgesia similar to that found in the hind paw. 
Different mechanisms therefore appear to underlie muscle and cutaneous 
inflammatory hyperalgesia, regardless of the site used to investigate cutaneous 
inflammation. One of the consequences of the poor understanding of muscle pain is 
the lack of a reliable regimen for treating human muscle pain, including delayed-onset 
muscle soreness (DOMS). DOMS, which has a partial inflammatory pathogenesis, is 
not relieved by non-selective cyclo-oxygenase inhibitors. This phenomenon may be 
that prostaglandins are not produced peripherally or centrally, when muscle tissue is 
damaged. I investigated the effect of inhibiting cyclo-oxygenase-2, the isoform released 
during inflammation, on DOMS in human volunteers. I found that rofecoxib, a cyclo-
oxygenase-2 inhibitor, did not attenuate DOMS and nor did tramadol, a central-acting 
analgesic. The neurochemical pathway underlying DOMS therefore appears to be 
distinct from the pathways which underlie pain and hyperalgesia in other syndromes. 
Future research should include investigations into the central mechanisms of muscle 
pain and blocking the action of IL-1β and CINC-1 both peripherally and centrally may 
prove a beneficial target for the treatment of clinical muscle pain.  
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CHAPTER 1 
 
 
 
INTRODUCTION 
 2 
Muscle pain is a common morbidity affecting all people at some stage of their lives 
with a prevalence of at least 20% within the western world (Brooks, 2005). The 
prevalence of musculoskeletal pain also is increasing as the age of the general 
population increases (Siebens, 2007). Because there is a common comorbidity of 
musculoskeletal pain with other diseases, for example muscle pain in cancer patients, 
fibromyalgia associated with posttraumatic stress disorder, and rotator cuff injury after 
a cerebrovascular accident (Siebens, 2007), it is vital that optimal treatment is found for 
musculoskeletal pain while minimising the side-effects of the treatment. The 
mechanisms underlying muscle pain were first investigated by Kellgren, in 1938, who 
injected hypertonic saline into muscle and identified characteristic patterns of pain 
from each muscle (Kellgren, 1938). Siegfried Mense, a pioneer in the field of muscle 
pain, in the late 1970’s investigated the electrophysiological pathways involved in 
muscle hyperalgesia (Mense, 1977). Although some studies have been conducted on 
muscle pain, the most current information about muscle pain has been inferred from 
studies investigating the mechanisms of cutaneous pain. Over the last few decades, it 
has become apparent that the mechanisms of muscle pain are distinct from that of 
cutaneous pain, and therefore many inferences may be inaccurate. 
 
Although the mechanism of clinical muscle pain is not yet clear, there is an emergence 
of information implying that the origin of most clinical muscle pain may lie in 
inflammatory pathways activating peripheral muscle nociceptors, leading to peripheral 
sensitization, and finally  progressing to central sensitization (Inanici & Yunus, 2004; 
Murata et al., 2005). The aim of my introduction is to survey the literature on the role 
that pro-inflammatory cytokines and related inflammatory mediators play in primary 
hyperalgesia and, more specifically, in experimental models of primary muscle 
hyperalgesia. A confounding factor in examining the mechanisms of inflammatory 
 3 
muscle pain is that exercise alone is able to induce a cytokine response similar to that 
of an inflammatory response, but with the absence of pain. Therefore, in order to 
understand whether inflammatory mediators are likely to contribute to muscle pain, I 
must account for the role that cytokines play during exercise. Finally, I will investigate 
the role of inflammatory mediators in clinical muscle pain. 
 
1. Inflammation 
Inflammation is a common cause of pain, and more often hyperalgesia, and the 
treatment of inflammation contributes to a large proportion of the global 
pharmaceutical sales. Inflammatory pain and the treatment of inflammatory pain have 
been investigated extensively, but most treatment regimens are based on findings from 
studies conducted on cutaneous tissue. Although a similar process to that in cutaneous 
tissue occurs in other tissues and organs during inflammation, the sequence of events 
and severity of inflammation differ depending on the tissue involved. To identify 
whether the inflammatory process in muscle is similar to that of cutaneous tissue, it is 
necessary to understand the inflammatory mediators that contribute to cutaneous 
inflammation and the associated pain. 
 
Inflammation can occur as a result of chemical, thermal or mechanical injury. The 
purpose of inflammation is to alert the organism to the injury and promote healing and 
repair of the damaged tissue (Smith, 1991). The inflammatory process involves both 
vascular changes and a cellular response. Inflammatory mediators are released from the 
injured tissue, stimulating an increased blood flow to the area and an increased capillary 
permeability leading to local oedema, increased temperature and redness. 
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The local vasodilation of the arterioles during inflammation allows for the influx of 
leukocytes and chemical mediators into the injured and surrounding area. Neutrophils 
are the first to invade the injured area, followed by monocytes and lymphocytes. The 
neutrophil invasion, aiding the digestion of the injured cells, is rapid and brief (Smith, 
1991). Hours later, monocytes migrate to the area and remain there for several days. 
Once monocytes enter the tissue they mature into macrophages and aid in the removal 
of foreign debris and necrotic tissue. The leukocytes release growth factors and 
cytokines which degrade the injured tissue, but also are important mediators in the 
proliferative phase of wound repair (Smith, 1991). In addition, the growth factors and 
cytokines contribute in producing hyperalgesia, or an increased sensitivity to a painful 
stimulus. Cytokines are soluble proteins that act at very low concentrations in an 
autocrine, paracrine or endocrine function (Moldoveanu et al., 2001). The pro-
inflammatory cytokines that are present during inflammation and that contribute 
towards inflammatory hyperalgesia are tumour necrosis factor alpha (TNF-α), 
interleukin-1beta (IL-1β), interleukin-6 (IL-6) and, cytokine-induced neutrophil 
chemoattractant (CINC-1) in rats or interleukin-8 (IL-8) in humans (Poole et al., 
1999a). 
 
1.1 Inflammatory hyperalgesia 
 
Various chemical mediators, released from immune cells and resident cells, are 
involved in sensitizing or directly activating nociceptors by acting on receptors and ion 
channels on the nociceptors. Peripheral sensitization of the nociceptors occurs by 
lowering the threshold to a stimulus, usually of a thermal or mechanical quality, leading 
to hyperalgesia, an increased sensitivity to a noxious stimulus, and allodynia, an 
increased sensitivity to a non-noxious stimulus (Mitchell, 1999). The nociceptor 
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threshold is lowered by gene translation, transcription and post-translation changes in 
the receptors and ion channels, for example increasing the TRPV1 receptor expression 
via mitogen-activated protein kinases and therefore making the nociceptors more 
sensitive to stimuli (Costigan & Woolf, 2000; Meyer et al., 2006). This peripheral 
sensitization results in phenotypic changes in sensory neurones from inflamed tissue 
and changes within the spinal cord such as altered transduction sensitivity of high-
threshold nociceptors and a change in excitability of spinal neurones (Woolf et al., 
1997). Some mediators affect transduction directly through changes within ion 
channels, while others, such as cytokines, act on gene transcription of nociceptors 
creating peripheral hypersensitivity. Cytokines may act on cytokine receptors found on 
the nociceptors, for example TNF-α, or stimulate the release of other cytokines or 
chemical mediators, which in turn activate or sensitize nociceptors, leading to 
nociceptor transduction or neuronal transcription (Woolf et al., 1997).  
 
In addition to peripheral sensitization of nociceptors during inflammation, antidromic 
afferent nerve activity causes the release of neurotransmitters in other branches of the 
afferent nerve resulting in neurogenic inflammation. (Meyer et al., 2006). Neurogenic 
inflammation results in further local vasodilation and increased vascular permeability, 
perpetuating the inflammatory process. The nociceptors in the injured tissue release 
neuropeptides, such as calcitonin growth-related peptide (CGRP) and substance P, into 
the interstitium promoting a further increase in vascular permeability and sensitizing 
and activating surrounding nociceptors (Opree & Kress, 2000; Bianchi et al., 2004). 
The neurotransmitters released exacerbate the influx of leukocytes and the release of 
pro-inflammatory mediators, including cytokines, and other direct activators of 
peripheral nociceptors, such as bradykinin. 
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1.1.1 Bradykinin 
 
Bradykinin is released into the interstitium as a result of injury to tissue. Bradykinin is a 
short-acting, but potent, vasodilator and is formed from the enzymatic action on 
kallikrein, and broken down quickly by carboxypeptidase. Bradykinin is able to 
stimulate nociceptors directly by acting on B1 and B2 receptors found on nociceptors, 
but B1 receptors requires the presence of cytokines to be activated by bradykinin 
during inflammation (Poole et al., 1999b). Once inflammation is established, blocking 
both B1 and B2 receptors does not attenuate mechanical hyperalgesia (Poole et al., 
1999a). Also, blocking B1 receptors does not attenuate the mechanical hyperalgesia 
induced by other inflammatory mediators, such as TNF-α, IL-8 or prostaglandin E2 
(Poole et al., 1999a). Therefore, although bradykinin is able to activate nociceptors 
directly through bradykinin receptors, other mediators are required to sustain the 
inflammatory hyperalgesia.  
 
1.1.2 Tumour necrosis factor alpha  
 
Tumour necrosis factor alpha (TNF-α) is a pleiotropic cytokine, a potent pyrogen, and 
initially was called cachectin for its catabolic effects during disease. TNF-α is a 17kDa 
protein that acts in cytolysis, mitogenesis, recruiting leukocytes to an injured area by 
inducing the expression of surface adhesion molecules allowing for adhesion of 
leukocytes, and stimulating the release of IL-1β, IL-6 and IL-8 (Woolf et al., 1997). It 
has potent paracrine and endocrine functions and often acts in combination with other 
cytokines. TNF-α is secreted by most cells, including monocytes, macrophages and 
myocytes, and plays a critical role in the acute phase response of fever and cutaneous 
inflammation. Most cells within the body express receptors for TNF-α and therefore 
are able to respond to TNF-α (Moldoveanu et al., 2001). 
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TNF-α binds to two receptors, namely TNF-receptor one and TNF-receptor two. 
These two receptors have different intracellular domains and therefore exert different 
cellular responses (Zhang et al., 2000). TNF-α is cleared from the circulation by binding 
to a TNF-α binding protein, thus inactivating the TNF-α but also making it more 
biologically stable (Moldoveanu et al., 2001). The complex of TNF-α and binding 
protein are then metabolised mainly by the liver but also by the kidneys (Moldoveanu 
et al., 2001). 
 
TNF-α mediates hyperalgesia by decreasing the nociceptor threshold and triggering the 
release of other pro-inflammatory cytokines which further contribute to peripheral 
sensitization (Bianchi et al., 2004). Injecting inflammatory agents such as carrageenan 
and complete Freund’s adjuvant (CFA) into the hind paw of rats induces inflammatory 
hyperalgesia with an associated release of TNF-α in the hind paw, remaining elevated 
for at least 15 days (Woolf et al., 1997). Neutralizing TNF-α with antibodies co-
administered with CFA into the hind paw decreases the initial hyperalgesia, but by 24h 
the hyperalgesia has returned (Woolf et al., 1997). A possible explanation for this 
transient attenuation of the hyperalgesia is the brief activity of the TNF-α within the 
inflamed hind paw, or it may be that TNF-α is important for the initiation of 
inflammatory hyperalgesia while other mediators sustain the inflammatory 
hyperalgesia. Table 1 summarizes research using exogenous TNF-α to induce 
experimental hyperalgesia in the hind paw of rodents. 
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Reference 
Woolf et al, 1997 
Cunha et al, 1992 
Cunha et al, 2000 
Poole et al, 1999a 
Cunha et al, 2005 
Response to 
intervention 
Decrease in mechanical 
and thermal hyperalgesia 
Abolish hyperalgesia 
Attenuate hyperalgesia 
Attenuate hyperalgesia 
Attenuate hyperalgesia 
Attenuate hyperalgesia 
Abolish hyperalgesia 
Abolish hyperalgesia 
Attenuate hyperalgesia 
Abolish hyperalgesia 
No effect 
 
Intervention 
Block NGF 
Block TNF-α 
Block IL-1 
Block IL-6 
Block IL-8 
Block IL-1 and IL-6 
Block IL-1 and IL-8 
Block IL-6 and IL-8 
IL-1ra 
Block TNF-α 
Block B1 receptors 
 
Response to noxious stimulus 
Dose dependent intensity of thermal 
and mechanical hyperalgesia lasting 
6h 
1-3h mechanical hyperalgesia 
Dose dependent intensity 
  
  
  
  
  
Mechanical hyperalgesia 1h after 
injection 
Mechanical hyperalgesia 3h after 
injection 
Dose and time dependent mechanical 
hyperalgesia 
Table 1. Summary of research investigating TNF-α injected into the hind paw of rodents to produce hyperalgesia 
Dose of TNF-α 
1-500ng (rat) 
0.0025-2.5pg (rat) 
2.5pg (rat) 
2.5pg (rat) 
1-1000pg (mouse) 
             B1 receptor – bradykinin 1 receptor, IL-1ra – interleukin one receptor antagonist,                                     
T          TNF-α – tumour necrosis factor alpha, species in parentheses indicate the rodent used for each experiment. 
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In peripheral inflammation, no TNF-α is detected in the circulation. However, TNF-α 
has been detected in other tissues, such as the contralateral paw, which were not 
directly affected by the inflammation and did not present with hyperalgesia (Woolf et 
al., 1997; Bianchi et al., 2004). Also, injecting TNF-α into the hind paw, without the 
stimulation of a noxious challenge, does not stimulate the release of the 
neurotransmitter calcitonin growth-related peptide (CGRP) within the injected paw, 
inferring that no nociceptor activation or development of neurogenic inflammation 
occurred. In the presence of a noxious thermal challenge, TNF-α administration 
significantly increases the CGRP concentration above that observed with a noxious 
thermal challenge alone (Opree & Kress, 2000). Therefore, TNF-α requires a 
concurrent noxious stimulus in order to sensitize nociceptors. 
 
TNF-α may contribute to the induced hyperalgesia by stimulating prostaglandin 
synthesis via IL-1β and IL-6, and activate adrenergic receptors via IL-8 (Cunha et al., 
1992). Hyperalgesia induced by local injection of TNF-α into the hind paw of rats was 
attenuated by neutralizing IL-1β, IL-6 and IL-8 individually, and abolished by 
neutralizing a combination of  IL-1β and IL-6, or IL-6 and IL-8 or IL-1β with IL-8 
(Cunha et al., 1992), implying that the cytokines released down-stream of TNF-α play a 
greater role in maintaining the hyperalgesia than the TNF-α itself.  
 
Therefore, TNF-α alone does not activate nociceptors producing spontaneous pain, 
but sensitizes nociceptors to noxious stimuli and so produces hyperalgesia. Also, TNF-
α stimulates the release of other inflammatory mediators, in particular other cytokines, 
which may sensitize nociceptors or stimulate the release of other chemical mediators 
that directly activate nociceptors.  
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1.1.3 Interleukin-1 beta  
 
Interleukin-1β is a 17kDa protein that is cleaved from the precursor pro-IL-1β by IL-
1β converting enzyme, an intracellular protease also called caspase-1 (Authier et al., 
1999; Zhang et al., 2000). Interleukin-1β is mostly secreted by macrophages and 
monocytes (Rothwell & Luheshi, 2000), and is important for attracting and 
coordinating the responses of immune cells during infection or inflammation. 
Interleukin-1β is detected only in pathological states, is a pleiotropic cytokine, and is 
involved in inducing many of the sickness behaviours, such as fever, lethargy and also 
hyperalgesia (Watkins et al., 1995). Interleukin-1β also inhibits vascular smooth muscle 
contraction via the stimulation of nitric oxide, which may further exacerbate the 
symptoms associated with vasodilation that is induced during inflammation 
(Moldoveanu et al., 2001). 
 
IL-1β binds to one of two membrane-bound receptors, namely receptor type I and 
type II, using IL-1R accessory protein. IL-1βRI transduces an intracellular signal while 
IL-1βRII does not transduce an intracellular signal, but likely acts as a decoy receptor. 
Interleukin receptor antagonist is an endogenous antagonist to IL-1β and acts by 
competing for receptor sites thus blocking the action of IL-1β. 
  
Interleukin-1β release, stimulated by TNF-α, is a well described sensitizer of 
nociceptors that ultimately produces hyperalgesia in cutaneous tissue (Ferreira et al., 
1988). An injection of IL-1β into the hind paw of rats is able to induce mechanical 
hyperalgesia that is dose and time dependent (Cunha et al., 2000; Cunha et al., 2005). 
However, regardless of the dose of IL-1β administered, the hyperalgesia resolves 
within 24h. IL-1β is released during inflammation as an injection of CFA into the hind 
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paw produced an increase in hind paw tissue IL-1β concentration 48h after injection, 
which is concomitant with the hyperalgesia induced (Safieh-Garabedian et al., 1995). 
Although IL-1β is produced at the site of inflammation and IL-1β given systemically 
induces hyperalgesia, IL-1β is not detected in the circulation when inflammation is 
induced in the hind paw by inflammatory agents such as carrageenan or CFA (Ferreira 
et al., 1988; Safieh-Garabedian et al., 1995). Table 2 summarizes research using 
exogenous IL-1β to induce experimental hyperalgesia in the hind paw of rodents. 
 
Interleukin-1β does not directly activate nociceptors, as evident by the lack of CGRP 
release into tissue injected with IL-1β (Opree & Kress, 2000). However, IL-1β 
sensitizes nociceptors and produces hyperalgesia by stimulating the release of cyclo-
oxygenase enzyme (COX) which converts arachidonic acid into prostaglandins (Cunha 
et al., 1992). Interleukin-1β induces hyperalgesia through local peripheral sensitization, 
and is mediated via prostaglandin synthesis or nerve-growth factor (NGF) release 
stimulating trkA receptors (Ferreira et al., 1988). IL-1β also has central effects acting 
either via the vagal afferents (Watkins et al., 1995) or via central release of IL-1β 
(Samad et al., 2001) and, therefore, COX-2 centrally.  
 
Although IL-1β stimulates the release of other cytokines and cyclo-oxygenase, IL-8 
and IL-6 alone do not mediate its action, and blocking TNF-α does not attenuate IL-
1β-induced hyperalgesia (Cunha et al., 1992). A combination of TNF-α and IL-1β 
injected into the hind paw of rats produced a hyperalgesia comparable to that found 
after 50µg carrageenan injected into the hind paw (Ferreira et al., 1988; Cunha et al., 
2000). Therefore, the hyperalgesia induced by inflammatory agents may be produced 
by TNF-α and IL-1β, with minor involvement by IL-6 and IL-8.  
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Reference 
Ferreira et al 
(1988) 
Cunha et al 
(2000) 
Cunha et al 
(2005) 
Safieh-
Garabedien et al 
(1995) 
Sachs et al 
(2002) 
Response to intervention 
Dose-dependent decrease in 
mechanical hyperalgesia induced by 
IL-1β 
Decreases intensity of hyperalgesia 
Increase intensity of hyperalgesia 
  
  
Abolish hyperalgesia 
Decrease in mechanical hyperalgesia 
induced by IL-1β 
Intervention 
Analogue to IL-1β (Lys-
D-Pro-Thr) 
IL-1ra 
 Block IL-1ra 
  
IL-1ra 
Indomethacin 
Atenolol and 
indomethacin 
Response to noxious 
stimulus 
Bilateral mechanical 
hyperalgesia except with low 
doses 
Mechanical hyperalgesia 3h 
after injection 
Dose and time dependent 
mechanical hyperalgesia 
Thermal but not mechanical 
hyperalgesia 
  
Table 2. Summary of research investigating il-1β injected into the hind paw of rodents to produce hyperalgesia 
Dose of IL-1β 
per paw 
0.25-2.5pg (rat) 
0.05pg and 
0.5pg (rat) 
10-1000pg 
(mouse) 
1pg, 100pg, 
1000pg (rat) 
0.5pg (daily for 
10-18days, rat) 
IL-1β – interleukin-one beta, IL-1ra – interleukin one receptor antagonist, species in parentheses indicate the rodent used for 
each experiment 
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Like TNF-α, IL-1β is not able to directly activate nociceptors producing spontaneous 
pain, but IL-1β is a potent hyperalgesic agent acting by sensitizing nociceptors, 
stimulating the release of prostaglandins and acting centrally within the spinal cord. In 
addition, IL-1β stimulates the release of other pro-inflammatory cytokines, such as IL-
6, and growth factors such as nerve growth factor NGF (Woolf et al., 1997).   
 
1.1.4 Interleukin-6 
 
Interleukin-6 is a 26kDa protein secreted by most cells in the body including myocytes. 
Interleukin-6, during inflammation, is a potent mediator for the release of acute phase 
proteins from the liver and plays a role as an inflammatory mediator in autoimmune 
diseases such as systemic lupus erythematosis and rheumatoid arthritis (Moldoveanu et 
al., 2001). IL-6 has only one receptor (Zhang et al., 2000; De Jongh et al., 2003) but two 
IL-6 receptor signalling proteins, gp80 and gp130, are upregulated during pain.  
 
Both TNF-α and IL-1β can stimulate the release of IL-6, and IL-6 influences the 
synthesis of substance P, NGF and prostaglandins (Poole et al., 1999a). IL-6 when 
injected into the hind paw is able to produce an intensity  of mechanical hyperalgesia 
comparable to that produced by intraplantar TNF-α administration. However, the dose 
of IL-6 required (10-1000pg) is much greater than that of TNF-α (Cunha et al., 1992). 
Also, blocking IL-6 only attenuated carrageenan-induced hyperalgesia, whereas 
blocking TNF-α abolished carrageenan-induced hyperalgesia (Cunha et al., 1992).  
 
IL-6 is the least potent hyperalgesic agent of the pro-inflammatory cytokines (Poole et 
al., 1999a), but IL-6 does partly drive the production of prostaglandins, via cyclo-
oxygenase, which then activate or sensitize nociceptors. IL-6 does contribute to 
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inflammatory hyperalgesia since after inducing inflammation in IL-6 knockout mice, 
the mice are less responsive to a noxious thermal stimulus (Xu et al., 1997). IL-6, like 
TNF-α and IL-1β, is unable to activate nociceptors, as evident by a lack of CGRP 
release into tissue injected with IL-6. However, unlike TNF-α and IL-1β it also does 
not sensitize nociceptors unless there is the presence of soluble IL-6 receptors (Opree 
& Kress, 2000). Although gp130 signalling protein is constitutively expressed in normal 
tissue, the soluble IL-6 receptor is not (Opree & Kress, 2000). It is not clear what 
triggers the release of the soluble IL-6 receptors or if all tissues are able to express it 
and further work is required to investigate the interaction between IL-6 and the 
associated receptors. Nonetheless, IL-6 is biologically active only in the presence of 
both the soluble receptor and the signalling protein gp130 (Song & Kellum, 2005). 
 
Although IL-6 is present during inflammation, it requires the presence of a soluble IL-
6 receptor and gp130 signaling protein to produce hyperalgesia, and therefore, may 
contribute to sensitizing nociceptors during inflammation in combination with other 
mediators such as IL-1β.  
 
1.1.5 Cytokine-induced neutrophil chemoattractant-1 and interleukin-8 
 
Cytokine-induced neutrophil chemoattractant (CINC-1) is a small 8kDa protein, 
originally identified in isolated rat epithelial cell lines (Yamamoto et al., 1998), and is 
categorised as a chemokine. Subfamilies of chemokines exist, depending on the site of 
one or two cysteine residues, with each group attracting a certain type of leukocyte 
(Lorenzetti et al., 2002). Interleukin-8 and CINC-1 belong to the same cysteine-amino 
acid-cysteine (CXC) family with CINC-1 being the rat homologue to human IL-8. 
Lipopolysaccaride (LPS), the pyrogenic cell wall of Gram positive cocci, TNF-α, and 
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IL-1β, all are able to induce the release of CINC-1 into circulation (Yamamoto et al., 
1998; Campbell et al., 2003). CINC-1 induces transient neutrophil accumulation 
without the migration of lymphocytes or monocytes (Matsumoto et al., 1997). CINC-1 
also may act as an early acute phase protein during inflammation (Campbell et al., 
2003), and it has potent angiogenic properties (Akerstrom et al., 2005). 
 
The receptors for CINC-1 or IL-8 have yet to be identified, and whether any of these 
receptors are present on nociceptors is still to be investigated. However, IL-8 injected 
into the hind paw of a rat is able to produce a dose-dependent hyperalgesia peaking in 
intensity at 6h and resolving by 24h (Cunha et al., 1991). Table 3 summarizes research 
using exogenous CINC-1 or IL-8 to induce experimental hyperalgesia in the hind paw 
of rodents. 
 
IL-8 may contribute to hyperalgesia, but its effects are likely to occur downstream of 
IL-1β, IL-6, TNF-α. (Cunha et al., 1992). Blocking CINC-1 attenuated carrageenan-
induced hyperalgesia and TNF-α-induced hyperalgesia in the hind paw, but if both 
CINC-1 and IL-1β were blocked, both types of hyperalgesia were abolished 
(Lorenzetti et al., 2002). Therefore, the release of CINC-1 is stimulated by TNF-α, but 
the mechanism of hyperalgesia induced by CINC-1 is independent of IL-1β and TNF-
α. 
 
CINC-1 produces hyperalgesia via adrenergic receptor activation as evidenced by 
attenuation of hyperalgesia by administration of atenolol, a beta-adrenergic antagonist, 
but not indomethacin, a non-specific cyclo-oxygenase inhibitor (Cunha et al., 1991; 
Cunha et al., 1992; Lorenzetti et al., 2002). IL-8, with or without the stimulation of a 
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Poole et al (1999) 
Lorenzetti et al 
(2002) 
Cunha et al 
(2000) 
Sachs et al (2002) 
Cunha et al 
(2005) 
Cunha et al 
(1991) 
Response to intervention 
No change 
No change 
Attenuate hyperalgesia 
No change 
Abolish hyperalgesia 
No change 
Decrease in mechanical 
hyperalgesia induced by 
CINC-1 
  
Attenuate hyperalgesia 
Attenuate hyperalgesia 
Attenuate hyperalgesia 
Intervention 
Block B1 
receptors 
Indomethacin 
Atenolol 
Block IL-1 
Block CINC-1 
IL-1ra 
Atenolol 
  
Atenolol 
Propanolol 
Guanethidine 
Response to noxious 
stimulus 
mechanical hyperalgesia 3h 
after injection 
Mechanical hyperalgesia 
measured 3h and 6h after 
injection 
Mechanical hyperalgesia 3h 
after injection 
  
Dose and time dependent 
mechanical hyperalgesia 
Dose dependent mechanical 
hyperalgesia (3h after 
injection) 
Table 3. Summary of research investigating CINC-1 and IL-8 injected into the hind paw of rodents to produce 
hyperalgesia 
Dose of CINC-1 or IL-8 
0.1ng (rat) 
3-300pg (rat) 
10pg and 100pg (rat) 
100pg (daily for 10-18 
days, rat) 
1-10ng (mouse) 
1pg, 10pg and 100pg (rat) 
B1 receptor – bradykinin one receptor, IL-1ra – interleukin one receptor antagonist, CINC-1 – cytokine-induced neutrophil 
chemoattractant, IL-1 – interleukin 1, species in parentheses indicate the rodent used for each experiment. 
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noxious challenge, does not activate or sensitize nociceptors (Opree & Kress, 2000), 
suggesting that IL-8 may produce hyperalgesia through central effects, acting on the 
spinal cord or the brain, but not through direct nociceptor activation. CINC-1 injected 
into one hind paw produces a dose-dependent mechanical hyperalgesia in both hind 
paws further implicating a central, rather than peripheral role for CINC-1 (Lorenzetti et 
al., 2002). 
 
CINC-1 may play a role centrally by acting on the anterior pituitary and hypothalamus 
(Matsumoto et al., 1997). A painful stimulus, such as a formalin injection into the hind 
paw, increases the serum CINC-1 concentration and increases the CINC-1 
concentration in the hypothalamus. Whether CINC-1 is released from the 
hypothalamus and anterior and posterior pituitary, or is released elsewhere and acts on 
these target organs, is still to be determined. However, CINC-1, injected 
intracerebroventricularly, induces mechanical hyperalgesia (Yamamoto et al., 1998). 
Interestingly, macrophage-inflammatory protein (MIP-1), a chemokine for monocytes, 
does not induce hyperalgesia, suggesting that either CINC-1 itself is able to bind to 
receptors within the pain pathway and induce hyperalgesia, or the neutrophils that are 
attracted to the inflamed area release mediators that are able to induce hyperalgesia.  
 
Therefore, CINC-1 or IL-8 is able to produce hyperalgesia, independent of TNF-α and 
IL-1β, with the most likely mechanism being through central mediation. Further work 
into the role of CINC-1 and IL-8, such as the receptors and the mechanism of 
inducing hyperalgesia, is required. 
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1.1.6 Prostaglandins 
 
Prostaglandins and prostacyclins are potent peripheral vasodilators and act 
synergistically in producing oedema and inflammatory pain (Baldwin Lanier, 2003). 
Prostaglandins are able to sensitise nociceptors, but also increase vascular permeability 
and allow other mediators into the injured tissue, which may further sensitize 
nociceptors (Baldwin Lanier, 2003). Prostaglandins are synthesized from membrane 
lipids via cyclo-oxygenase enzyme (Samad et al., 2001). Cyclo-oxygenase (COX) is the 
rate-limiting enzyme that converts arachidonic acid into prostaglandins. Figure 1 
below, taken from Hinz and Brune (2002), shows the process by which prostaglandins 
are synthesized from arachidonic acid. 
 
 
Figure 1.  The prostanoid synthesis cascade, and the physiological and 
pathophysiological effects of the COX isoenzymes (Hinz & Brune, 2002).  
 
Three isoforms of the cyclo-oxygenase enzyme have been identified: COX-1, COX-2 
and COX-3. Cyclo-oxygenase-1 is the housekeeping enzyme, responsible for regulating 
homeostatic function such as platelet function and gastric mucosa (Hinz & Brune, 
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2002), but may also be involved centrally in incisional pain (Zhu et al., 2003). Cyclo-
oxygenase-3 isoform, found in the central nervous system, behaves in a similar manner 
to COX-2, and both COX-2 and COX-3 have been identified in the central nervous 
system (Graham & Scott, 2005). Cyclo-oxygenase-2 is the adaptive COX, which is 
released peripherally during tissue injury and inflammation resulting in prostaglandin 
synthesis, and not found in normal non-injured tissue (Baldwin Lanier, 2003). 
 
Prostaglandins released during inflammation and injuries sensitize nociceptors. 
Although it has been known that prostaglandins contribute towards peripheral 
sensitization, the mechanism has been only recently elucidated. Prostaglandins bind to 
prostaglandin receptors, found on primary afferent nerves, decreasing the threshold of 
voltage-gated sodium channels, tetradoxin-resistent sodium channels (Gold et al., 
1996). In addition to direct activation of prostaglandins receptors, indirect activation of 
the peripheral nociceptor occurs making the nociceptor more sensitive to other 
mediators such as bradykinin and heat. These actions of prostaglandins are thought to 
occur via inhibition of voltage-gated potassium currents via activation of protein 
kinase-A and altering the sensitivity of TRPV1 receptors (Gold et al., 1996; Lopshire & 
Nicol, 1998; Burian & Geisslinger, 2005). 
 
In summary, numerous chemical mediators, including cytokines, contribute to 
inflammatory hyperalgesia either via direct activation of receptors, such as bradykinin, 
or sensitization of nociceptors such as prostaglandin. Much research still needs to be 
conducted regarding the mechanisms behind cytokines sensitizing nociceptors. 
Although a clear pro-inflammatory cytokine cascade has been described (Poole et al., 
1999a), identifying whether the cytokine, such as IL-1β,  sensitizes nociceptors itself, or 
via mediators released downstream of IL-1β has not been clearly investigated. 
 20 
Inflammatory hyperalgesia is common in all tissues, and further research is required to 
fully understand the mechanisms underlying this common ailment in all tissues, 
especially muscle. 
 
2. Muscle pain 
2.1 Muscle hyperalgesia  
 
Muscle pain is different to cutaneous pain in that muscle pain is a poorly localized, dull 
aching pain, while cutaneous pain is sharp and well localized (Mense, 1991). Muscle 
pain can be spontaneous, such as an active trigger point and myofascial pain. The pain 
associated with muscle injury can spread to adjacent muscles and other deep structures, 
with common patterns of referred pain (Mense, 1991; Simons et al., 1999). Muscle 
hyperalgesia, usually mechanical hyperalgesia, is identified by applying a blunt pressure 
to the muscle (Treede et al., 2002). The presence of mechanical hyperalgesia is used to 
diagnose muscle conditions such as fibromyalgia and myofascial pain (Nampiaparampil 
& Shmerling, 2004; Ferna´ndez-de-las-Pen˜as et al., 2007).  
 
Muscle nociceptors respond to numerous chemical stimuli and to high-intensity 
mechanical stimuli. Muscle nociceptors are high-threshold receptors predominantly 
located in the wall of arterioles and in the surrounding connective tissue (Mense, 1993; 
Mense, 2003). They are free nerve endings on group III (thinly myelinated) and group 
IV (unmyelinated) afferent fibres (Mense, 1993). Although the mechanism by which 
mechanical stimuli lead to signal transduction is not entirely clear, muscle nociceptors 
are slow-adapting, high-threshold mechanoreceptors that respond to noxious blunt 
pressure (Treede et al., 2002). 
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Various receptors are found on muscle nociceptors, including purinergic P2X3 
receptors that respond to adenosine triphosphate (ATP) and vanilloid TRPV1 
receptors that respond to hydrogen ions and capsaicin (Sluka, 2002; Rukwied et al., 
2007). Acid-sensitive ion channels (ASIC) have been identified in primary muscle 
afferents and the associated dorsal horn cells, with ASIC3 channels mediating the 
development of secondary mechanical hyperalgesia after repeated injection of acidic 
saline (Sluka et al., 2003). Other substances such as serotonin, glutamate, bradykinin 
and cytokines induce muscle hyperalgesia, but which receptors are activated and where 
they are situated is still to be elucidated (Babenko et al., 1999; Skyba et al., 2002; Mense, 
2003; Schafers et al., 2003; Svensson et al., 2003; Fernandez-De-Las-Penas et al., 2007; 
Rukwied et al., 2007; Svensson, 2007).  
 
Some substances are able to produce more intense pain than are other substances. 
Bradykinin, for example, is able to induce muscle pain of a greater intensity than that 
induced by serotonin or substance P (Babenko et al., 1999). Although chemical 
mediators, such as bradykinin and serotonin, are able to induce muscle pain through 
peripheral sensitization, central sensitization develops very effectively in muscle pain, 
(Mense, 1993). It is not clear whether the time for central sensitization to develop 
differs between cutaneous tissue and muscle tissue but hyperalgesia in muscle tissue is 
usually associated with central sensitization. Allodynia is defined by the International 
Association for the Study of Pain as pain due to a stimulus which does not normally 
provoke pain. Excitation of primary muscle nociceptors results in an increased release 
of substance P and glutamate from the presynaptic terminal of primary muscle 
afferents. Glutamate and substance P act on the post-synaptic n-methyl d-aspartate 
(NMDA) and neurokinin-1 receptors, respectively, increasing the excitability of the 
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dorsal horn neurones (Mense, 2003), and so produce neuronal changes leading to 
central sensitization and symptoms such as referred pain.  
 
Referred pain arising from muscle is thought to arise from an increased receptive field 
of the dorsal horn neurones that occurs with central sensitization (Mense, 1993). 
Therefore, adjacent neurones innervating agonist muscles and adjacent muscles may be 
stimulated with the result that pain is perceived in non-injured muscle or tissue. 
Afferent muscle fibres converge on second order neurones in the dorsal horn with 
numerous other inputs. It is possible that there is increased substance P and CGRP 
release, resulting in the presence of referred pain. However, this evidence only is 
present in referred pain with pancreatitis and not muscle pain (Wick et al., 2006). 
Further studies are required to identify whether the same neurotransmitter release 
occurs with referred muscle pain. 
 
The mechanisms underlying the quality and area of referred and local pain associated 
with muscle injury still need to be investigated. Various models in both humans and 
animals are used to understand the mechanisms of peripheral and central sensitization 
during muscle pain since no ideal comparative model to clinical muscle pain has arisen. 
Muscle hyperalgesia in animal models such as the cat or the rat, exhibits characteristics 
comparable to those found in human experiments and therefore may be a reliable 
model to investigate the mechanism of human muscle pain (Mense, 1993; Kehl & 
Fairbank, 2003). 
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2.2 Clinical muscle pain 
 
It is possible that inflammation is an initiator of clinical muscle pain syndromes, 
including fibromyalgia, lower back pain and chronic whiplash (Koelbaek Johansen et 
al., 1999; Wallace et al., 2001; Blanco et al., 2005; Murata et al., 2005). Although the 
disease process progresses to central sensitization and pathological pain, it is possible 
that treating the initial inflammation, if it is present, may prevent the development of 
chronic pain and produce better clinical outcomes. Unfortunately, current treatment 
for inflammation is ineffective for muscle inflammation and therefore novel treatments 
targeting the mechanisms of muscle pain should be sought. Although the most 
frequent treatment given for muscle pain is non-steroidal anti-inflammatory drugs, 
which target prostaglandin synthesis, very little evidence exists that prostaglandins are 
produced during experimental and clinical muscle pain.  
    
Fibromyalgia is a chronic diffuse musculoskeletal pain, defined by the American 
College of Rheumatology as a decreased pain threshold in a minimum of 11 out of a 
possible 18 tender muscle sites (Wolfe et al., 1990). Although the exact mechanism of 
fibromyalgia is not clear, it is thought that there is central sensitization and changes in 
pain modulatory pathways (Treede et al., 2002; Petzke et al., 2003), since patients are 
sensitive not only to blunt pressure at the tender sites, but also have increased 
sensitivity to electrical stimulation, radiant and cutaneous heat, and cold stimulation 
(Petzke et al., 2003). Nonetheless, it does appear that peripheral mechanisms are not 
involved in the maintenance of the pain, although peripheral activation and possibly 
inflammatory mediators must be involved in the initiation of the pathology.  
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Researchers have found elevated circulating concentrations of IL-6 and IL-8 in patients 
with fibromyalgia compared to those of age and gender matched control subjects 
(Wallace et al., 2001). Although these cytokines are pleiotropic and fibromyalgia 
presents with multiple symptoms, such as fatigue and insomnia, further investigations 
into the possible role that cytokines may play in the musculoskeletal pain associated 
with fibromyalgia are warranted. Although muscle biopsy samples from patients 
diagnosed with fibromyalgia show no overt inflammatory response, there is necrosis 
and atrophy in the painful muscle with associated sarcolemmal disruption (Kalyan-
Raman et al., 1984; Yunus et al., 1989). Also, these muscle biopsy samples were taken 
in patients with well established fibromyalgia and by the time the biopsies were taken, 
evidence of inflammation may have subsided. 
  
Another common musculoskeletal complaint is myofascial pain which occurs in a 
regional site, as opposed to fibromyalgia which is generalised muscle pain. Myofascial 
pain can produce local spontaneous pain, referred pain, and pain elicited by mechanical 
pressure on trigger points, or points of tenderness (Simons et al., 1999; Treede et al., 
2002). The trigger points are tight bands of muscle fibres that possess a local twitch 
response when pressure is applied and follow a characteristic referral pattern (Simons et 
al., 1999; Rivner, 2001). Again, the mechanism of myofascial pain is not clear, but 
proposed mechanisms include muscle spindle hyperactivity, neuronal hyperexcitability 
at the motor-end plate and hypoperfusion of a localised area in the muscle leading to 
ischaemia (Rivner, 2001; Borg-Stein & Simons, 2002). To date, muscle damage and 
inflammation have not been identified, yet there is increased presence of inflammatory 
cytokines, IL-1β and TNF-α in active trigger points. In addition bradykinin, CGRP 
and substance P are elevated in active muscle trigger points, as identified by 
microdialysis but not seen in latent trigger points or normal muscle (Shah et al., 2005). 
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Therefore, it is possible that muscle pain may emanate from inflammatory mediators 
released into the injured muscle. 
 
Numerous other musculoskeletal diseases, such as rheumatoid arthritis, tension-
headaches and low back pain, include a muscle pain component. The mechanisms of 
such complex musculoskeletal pains range from abnormal autoimmune responses to 
abnormal mechanical loading, leading to injury. Although part of the mechanism 
behind these diseases is clear, the mechanism behind the muscle pain is not. Indeed, 
unless we can understand the mechanisms behind experimental muscle pain, it is 
unlikely we will be able to identify the mechanisms behind the muscular component of 
more complex-mediated musculoskeletal pain. 
 
In summary, muscle pain is different to that of cutaneous pain. Experimental models 
of clinical muscle pain, such as exercise-induced muscle pain and pain generated by 
carrageenan injected into the muscle are useful to investigate the mechanisms of 
inflammatory muscle pain. Much is still unknown regarding the mechanisms of muscle 
pain, but it is likely that inflammatory mediators, such as cytokines, initiate the muscle 
pain, and that central sensitization occurs quickly and maintains the muscle pain. 
 
2.3 Experimental models of muscle pain 
 
Various models of muscle pain have been employed to investigate the mechanism of 
muscle pain, including exercise-induced muscle pain, muscle ischaemia, intramuscular 
injection of hypertonic saline, and injection of inflammatory agents into the muscle of 
animals. In human and rat experimental models, muscle pain is commonly induced by 
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an injection of hypertonic saline or other algogenic agents, such as bradykinin, 
serotonin, substance P, glutamate, NGF (Babenko et al., 1999; Svensson et al., 2003).  
 
Intramuscular hypertonic saline injection produces pain that mimics clinical muscle 
pain and is short-lasting if injected once into subjects, but longer-lasting if injected 
repeatedly into rats, or infused chronically into humans (Graven-Nielsen & Mense, 
2001; Sluka et al., 2001). Intramuscular hypertonic saline injection was first used in 1938 
by Kellgren to produce a short-acting muscle pain, where the intensity of pain was 
dependent on the volume of saline injected (Kellgren, 1938; Capra & Ro, 2004). Pain 
induced by injection of intramuscular hypertonic saline mimics clinical pain in its 
quality, and leads to the development of referred pain. However, injecting hypertonic 
saline does not allow for the investigation of peripheral mechanisms underlying muscle 
pain since the pain induced by 5% hypertonic saline exceeds pain induced by 
bradykinin, serotonin and substance P, all of which are known to be released during 
inflammation (Babenko et al., 1999). Hypertonic saline may directly activate 
nociceptors by rapidly changing the concentration of sodium or potassium in the 
muscle following injection (Graven-Nielsen et al., 1997a), which is unlikely to be the 
only change, or indeed even a primary event, that occurs in clinical muscle pain. Five-
percent hypertonic saline is thought to activate muscle nociceptors synapsing on wide 
dynamic range neurones within the dorsal horn, which may account for the referred 
pain (Capra & Ro, 2004). Therefore, intramuscular hypertonic saline injection is an 
ideal technique for activating muscle nociceptors and associated pathways, but will not 
mimic mechanisms of clinical inflammatory muscle pain.  
 
Muscle ischaemia is another technique used to induce the qualities of muscle pain with 
good effect (Graven-Nielsen & Arendt-Nielsen, 2003). The mechanisms of muscle 
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pain following ischaemia are complex and involve numerous tissues including skin, 
fascia and muscle. The mechanism of this muscle pain is not fully understood. A 
reduction in blood supply alone does not evoke pain, but a decrease in blood supply in 
conjunction with muscle contractions evokes pain rapidly (Mense, 1993). It is thought 
that the nociceptor activation is as a result of changes in pH (Graven-Nielsen et al., 
1997b; Graven-Nielsen et al., 2003; Hoheisel et al., 2004), and a release of bradykinin 
and adenosine (Graven-Nielsen & Arendt-Nielsen, 2003; Segerdahl & Karelov, 2004). 
These chemical mediators would then activate ASIC receptors on muscle nociceptors, 
comparable to those found to be activated by intramuscular injection of hypertonic 
saline (Sluka et al., 2003; Sluka et al., 2007).  
 
Another experimental pain that may provide further insight into the mechanism 
underlying clinical muscle pain is exercise-induced pain. Although pain can be 
experienced immediately after exercise, the most researched exercise-induced muscle 
pain is delayed-onset muscle soreness (DOMS). The mechanism of DOMS is not 
entirely clear. However, there do seem to be some similarities in the pathogenesis of 
DOMS compared to that of clinical muscle pain, especially the inflammatory 
component and the associated decrease in muscle function.  
 
A direct method for studying inflammatory muscle pain is through intramuscular 
injection of inflammatory agents. Carrageenan and CFA, in particular, have been used 
in rats and cats to induce inflammatory muscle pain (Berberich et al., 1988; 
Radhakrishnan et al., 2003). These models mimic myositis and allow us to investigate 
the mechanism and treatment of inflammatory-induced muscle pain. In addition, these 
inflammatory agents are used regularly to investigate the mechanisms of cutaneous 
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inflammatory pain, allowing comparisons between cutaneous and muscle inflammatory 
hyperalgesia to be made.  
 
Therefore, the most appropriate model to induce inflammatory muscle pain is injecting 
inflammatory agents into muscle. However, it is unethical to inject inflammatory agents 
such as carrageenan and CFA into humans. Therefore, an alternative needs to be 
sought for experimental inflammatory muscle pain in humans. Since DOMS may have 
an inflammatory component, it is currently the best experimental model to study 
inflammatory muscle pain in humans. Both injecting inflammatory agents into animals 
and DOMS will be discussed in more detail below. 
 
2.2.1 Delayed-onset muscle soreness 
 
Eliciting delayed-onset muscle soreness (DOMS) is an ideal method of inducing 
muscle pain in a controlled, experimental fashion. However, DOMS, is not only 
induced in the laboratory, but also afflicts people who participate in unaccustomed 
exercise. The muscle pain is experienced as a dull ache with associated tenderness and 
stiffness occurring 24-48h after unaccustomed and usually eccentric exercise, and 
resolves within 4-7 days after exercise (MacIntyre et al., 1995). The muscle pain or 
soreness experienced after exercise occurs on muscle contraction and on passive 
stretch of the muscle.  
 
Delayed-onset muscle soreness also can be induced in an animal model using forced 
lengthening contractions, simulating eccentric muscle contractions. The mechanical 
hyperalgesia that develops after forced lengthening contractions peaks 48h after the 
completion of muscle contractions, with complete resolution by four days after the 
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muscle contractions (Taguchi et al., 2005). Thus, the hyperalgesia in this model mimics 
the temporal pattern of muscle hyperalgesia found with DOMS in humans. 
 
There are three theories proposed to explain the mechanism of DOMS: myofibrillar 
damage, enzyme efflux, and inflammation (Cheung et al., 2003). Eccentric exercise 
produces muscle damage with an associated loss of dynamic and static strength 
(Willoughby et al., 2003). Eccentric exercise produces a higher force per active cross-
sectional area of muscle fibres compared to concentric exercise (Armstrong et al., 
1983). The high mechanical load results in myofibrillar damage, releasing calcium and 
adenosine triphosphate (ATP) amongst other substances from the myotubes. During 
muscle injury resulting from eccentric exercise, z-lines are damaged producing z-line 
streaming, and a disruption of sarcomeric organization (Friden & Lieber, 2001). The z-
lines seem to be more vulnerable to injury, than other parts of the muscle fibre, since 
type II muscle fibres have the narrowest and weakest z-lines and are more susceptible 
to injury than are type I muscle fibres (Cheung et al., 2003).  
 
Muscle injury also results in proteolysis of contractile and non-contractile proteins 
(Baldwin Lanier, 2003). Disruption of the sarcomere leads to a loss of calcium 
homeostasis. An increased uptake of calcium into the cell activates calcium-dependent 
proteases, such as calpains which cleave proteins and cause further muscular disruption 
(Tidball, 1995). The increase in intracellular calcium activates lysosomal and non-
lysosomal enzymes such as glucose-6 phosphate dehydrogenase, creatine kinase and 
lactate dehydrogenase, all of which are elevated 36-48h after eccentric exercise 
(Armstrong et al., 1983). These enzymes may be good markers of the extent of muscle 
injury. For example, creatine kinase (CK) is an intramuscular enzyme responsible for 
maintaining adequate ATP levels during muscle contraction and is released during 
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muscle damage (Armstrong, 1984). However, CK plasma concentrations only peak 48-
72h after the exercise, which does not correlate with the peak in muscle soreness 
occurring 24-48h after exercise. Therefore, although CK may give an indication of the 
extent of muscle injury, CK release does not correlate with the extent or duration of 
pain experienced (Friden & Lieber, 2001). 
 
Substances released during myofibrillar damage and other injuries resulting in muscle 
inflammation spark the initiation of an inflammatory soup. Numerous studies have 
shown that the initial inflammatory response is necessary for the breakdown of the 
muscle tissue, followed, by the reparative phase necessary for hypertrophy of the 
muscle. During muscle injury and inflammation, acute phase proteins (C-reactive 
protein, ferritin, heat shock protein 70) may be released, together with neutrophil 
mobilisation and activation (Cannon et al., 1991). Neutrophils are rapid invaders during 
inflammation (Pedersen & Hoffman-Goetz, 2000), and are involved in phagocytosis of 
cellular debris. Neutrophils possibly contribute to the injury after eccentric 
contractions of the skeletal muscle by producing adhesion molecules and reactive 
oxygen species (Pizza et al., 2005b). Neutrophil infiltration is elevated significantly 6h to 
3 days after eccentric muscle contractions, while macrophages are elevated only 3 days 
after eccentric muscle contractions (Pizza et al., 2005b). This increase in both 
neutrophil and macrophage count corresponded with the amount of myofibre damage, 
but has not been correlated to the extent of muscle pain experienced. In contrast, no 
neutrophil infiltration was found following forced lengthening contractions in rats 
(Lapointe et al., 2002). After forced lengthening contractions in mice (Pizza et al., 
2005b), downhill running in rats (Tsivitse et al., 2003), and after eccentric exercise in 
humans (Pizza et al., 2005a),  there is early migration of neutrophils to the exercised 
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muscle, suggestive of a degenerative state following muscle injury, regardless of species 
investigated.  
 
Since inflammation is thought to occur during DOMS, signs and symptoms of 
inflammation, such as swelling, pain, increased temperature and loss of function, 
should be apparent. Numerous studies have shown that swelling, loss of function and 
pain do exist in DOMS (for review see Smith 1991). However, increased muscle 
temperature is difficult to measure in human studies and there is a lack of biochemical 
evidence of inflammation, although the techniques currently available may not be 
sensitive enough to identify the presence of mild muscle inflammation. Even if 
inflammation is present, it is still not clear which of the mediators or mechanisms 
contribute to the soreness associated with the muscle damage.  
 
If the muscle pain during DOMS was attributed to inflammation, prostaglandins (PG) 
would be produced and the time of increased production would correlate to the 
muscle pain. An increase in muscle PGE2 has been detected 24h after eccentric 
exercise, as measured by microdialysis, but only during a muscle contraction and not at 
rest (Tegeder et al., 2002). In another study, both prostaglandin F2 and PGE2 were 
increased in non-contracting skeletal muscle after eccentric exercise (Trappe et al., 
2001). If PGE2 indeed is released from skeletal muscle after muscle-damaging eccentric 
exercise and contributed to the pain, then inhibiting prostaglandin release should be 
beneficial in treating DOMS.  
 
As mentioned previously, cyclo-oxygenase (COX) is one of the key enzymes that 
convert arachidonic acid into prostaglandins, and inhibiting COX is the most common 
treatment for decreasing inflammation and inflammatory pain. Numerous studies have 
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been conducted to investigate the efficacy of non-selective COX-inhibitors on DOMS 
(see Table 5 for a summary). However, most of these agents were ineffective in 
reducing pain associated with DOMS. Ibuprofen, for example, attenuated PGF2 
concentrations in muscle, but it did not attenuate the muscle soreness or the PGE2 
concentration (Trappe et al., 2001). Another non-selective COX-inhibitor, diclofenac, 
administered to rats after forced-lengthening contractions, produced an impairment to 
the repair process (Lapointe et al., 2002), without alleviating the hyperalgesia. COX-2 
gene expression in muscle peaks five days after a freeze injury, so it appears that  
COX-2 may be important for muscle regeneration following traumatic freeze injury 
(Bondesen et al., 2004), and blocking prostaglandin synthesis may be detrimental to the 
repair process after injury, without alleviating the muscle soreness. 
 
An effective way to alleviate muscle pain experienced after eccentric exercise was 
through prophylactic COX-inhibitor administration (Hasson et al., 1993; O'Grady et al., 
2000). It is possible that administration of COX-inhibitors is effective in blocking the 
production of DOMS, but once inflammation has been established and other 
mediators have been released, and central sensitization has occurred, the administration 
of COX-inhibitors is ineffective in reversing DOMS. Further research is required to 
identify the mechanism underlying the role of prostaglandins in muscle pain, in 
particular DOMS. 
 
Administration of a non-specific COX-inhibitor after exercise, regardless of the dose 
or drug administered, appears to be ineffective, or of limited effectiveness, in treating 
DOMS. A criticism of studies using COX-inhibitors in treating DOMS may be that the 
dose of the drug was inappropriate. However, high doses of aspirin and ibuprofen also 
have been used with little success (Donnelly et al., 1990; Barlas et al., 2000a). These 
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results show that either the wrong cyclo-oxygenase enzyme has been targeted or that a 
complex mechanism mediates DOMS. No studies have investigated the effect of a 
COX-2 inhibitor on DOMS, and therefore, the ineffectiveness of COX-inhibitors may 
be that the wrong isoform is being targeted rather than inflammation not playing a role 
in DOMS. 
 
Not only have antihyperalgesics, such as COX-2 inhibitors not been investigated in 
attenuating DOMS, but also little work has been done using analgesics. Central 
sensitization occurs more rapidly in muscle pain (Wall & Woolf, 1984) and therefore 
may contribute to the muscle pain in DOMS. Morphine administered after inducing 
DOMS in humans, and after forced lengthening contractions in rats attenuated the 
hyperalgesia in the muscle (Tegeder et al., 2003). However, codeine administration after 
eccentric exercise in humans did not attenuate DOMS (Barlas et al., 2000a). Further 
work is required investigating the role of central-acting analgesics in DOMS to identify 
which receptors and pathways are important in DOMS. 
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Reference 
Barlas et al 
(2000a) 
Cannavino et al 
(2003) 
Donnelly et al 
(1990) 
Donnelly et al 
(1988) 
Hasson et al 
(1993) 
Lecomte et al 
(1998) 
Class of drug 
Opioid 
COX-3 inhibitor 
COX-1 & 2 
inhibitor 
COX-1 & 2 
inhibitor 
COX-1 & 2 
inhibitor 
COX-1 & 2 
inhibitor 
COX-1 & 2 
inhibitor 
COX-1&2 
inhibitor 
Muscle  soreness 
No change 
No change 
No change 
Change in VAS from 
55mm (placebo) to  
30mm (ketoprofen) 
No change 
No change 
Prophylactic ibuprofen 
decreased muscle 
soreness 24h and 48h 
after  exercise 
Therapeutic ibuprofen 
decreased muscle 
soreness 48h after 
exercise 
  
VAS decreased from 
53mm to 39mm 
Drug intervention 
Codeine (60mg)  
Paracetamol (1000mg) 
Aspirin (900mg) 
  
Transdermal 10% 
ketoprofen 
Ibuprofen (1200mg before 
and 600mg QID) 
Diclofenac 50mg TDS) 
Ibuprofen (400mg) 
Naproxen (500mg) 
Table 4. Summary of research on the use of pharmacological treatment of delayed-onset muscle soreness in 
human subjects 
Exercise  
Eccentric elbow flexion 
(n=12 per group) 
  
Isometric concentric and 
eccentric quadriceps 
contractions (n=32) 
Downhill running  
(n=16 per group) 
Downhill running  
(n=20) 
Bench stepping  
(n= 5 per group) 
Eccentric leg extensions 
(n=20) 
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Reference 
O’Grady et al (2000) 
Pizza et al (1999) 
Sayers et al (2001) 
Tokmakidis et al (2003) 
Trappe et al (2001, 2002) 
Tegeder et al (2003) 
Howell et all (1998a) 
Howell et al (1998b) 
Class of drug 
COX-1&2 inhibitor 
COX-1&2 inhibitor 
COX-1&2 inhibitor 
COX-1&2 inhibitor 
COX-1&2 inhibitor 
COX-3 inhibitor 
Opioid 
COX 1&2 inhibitor 
COX 1&2 inhibitor 
Muscle  soreness 
Decrease in pain rating with 
prophylactic treatment 
No change 
19% decrease in VAS after 
100mg ketoprofen 
VAS decreased from 55mm 
to 38mm 
No change 
A decrease in VAS by 37% 
with M6G and 71% decrease 
with morphine 
No change 
No change 
Drug intervention 
Diclofenac (75mg BD) 
Ibuprofen (800mg 5d before 
and after, TDS) 
Ketoprofen (25mg, 100mg) 
Ibuprofen (400mg) TDS 
Ibuprofen (400mg) TDS 
Paracetamol (1500mg) TDS 
  
Morphine-6-β-glucuronide 
(M6G, 500ng.ml-1 of plasma) 
Morphine (100ng.ml-1 of 
plasma) 
Flurbiprofen (100mg TDS) 
started pre-exercise 
Ibuprofen (400mg QID, 
800mg QID) started pre-
exercise 
Exercise  
Bench stepping (n=54) 
Eccentric arm curls (n=10) 
Eccentric elbow flexors 
(n=48) 
Eccentric leg curls (n=19) 
Eccentric knee extension 
(n=24) 
Concentric and eccentric  
calf exercise (n=10) 
Eccentric elbow flexor 
exercise (n=15 per group)) 
Eccentric elbow flexor 
exercise (n=20 per group) 
COX- cyclo-oxygenase, BD, administered twice daily, QID, administered four times per day, TDS- administered three times per day, 
VAS-visual analogue scale 
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2.2.2 Injection of carrageenan and complete Freund’s adjuvant 
 
Carrageenan is a plant-based polysaccharide that induces neurogenic inflammation 
regardless of the site of administration. When injected into the muscle, carrageenan excites 
group III and group IV muscle afferent fibres, lowering the threshold to mechanical stimuli 
(Berberich et al., 1988). Carrageenan injected into the forelimb muscle of rats reduces the 
grip strength of the forelimb (Kehl et al., 2000) and increases the sensitivity to mechanical 
stimuli (Diehl et al., 1988; Radhakrishnan et al., 2003). Both decreased muscle strength and 
mechanical hyperalgesia, present in the carrageenan model, also are present in clinical 
muscle pain conditions.  
 
An intramuscular injection of carrageenan evokes leukocyte infiltration into the 
perivascular space 2h after administration (Diehl et al., 1988). The types of leukocytes, were 
not identified, in the study, but were concentrated around the capillaries and small 
arterioles, where nociceptors are present (Mense, 1993). Treatment of carrageenan-induced 
muscle inflammation with acetylsalicylic acid, a non-selective COX-inhibitor, showed that 
some muscle nociceptors still were sensitized after the COX-inhibitor, and therefore, likely 
to be sensitized by mediators other than prostaglandins (Diehl et al., 1988). These results 
confirm that various receptors are present on muscle nociceptors, with only a few 
responsive to prostaglandins. 
 
Complete Freund’s adjuvant (CFA), another inflammatory agent, produces a longer-lasting 
hyperalgesia compared to that of carrageenan, regardless of the tissue injected. When 
injected into the masseter muscle, CFA produced mechanical hyperalgesia and allodynia 
within 30min of injection, and TNF-α, IL-1β, IL-6 and CINC-2 and CINC-3 tissue 
concentrations (CINC-1 was not measured) were elevated 5h after injection (Watanabe et 
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al., 2005). Because the cytokines were detected only long after hyperalgesia and allodynia 
appeared, it is possible that the prominent pro-inflammatory cytokines measured may not 
have initiated the inflammatory muscle hyperalgesia, but may have sustained the 
hyperalgesia, while other mediators such as bradykinin, hydrogen ions and ATP may 
initiate the hyperalgesia (Babenko et al., 1999; Babenko et al., 2000). Clinical muscle pains 
also are characterized by sustained hyperalgesia and production of central sensitization but 
the pro-inflammatory cytokine release in the muscle has not been measured.  
 
3. The role of  cytokines in muscle  
3.1 Cytokines in muscle 
 
If inflammation is the key initiator behind muscle pain, it is necessary that we understand 
the role that key mediators, such as pro-inflammatory cytokines, play in muscle 
homeostasis. Cytokines have numerous functions other than contributing towards 
hyperalgesia. For instance, TNF-α may play a direct role in regulating muscle function and 
homeostasis, but also may induce insulin resistance and suppress protein synthesis (Zhang 
et al., 2000). TNF-α, expressed by myocytes, is able to downregulate the expression of the 
glucose transporter GLUT-4, therefore increasing insulin resistance and increasing lipolysis 
(Saghizadeh et al., 1996). The proposed hypothesis is that TNF-α release is suppressed in 
normal muscle. However, during certain diseases such as diabetes and rheumatoid arthritis, 
TNF-α suppression is downregulated such that TNF-α is able to exert catabolic effects on 
muscle (Petersen & Pedersen, 2005). 
 
In skeletal muscle, TNF-α and IL-1β stimulate the synthesis of nitric oxide, a potent 
vasodilator (Zhang et al., 2000). The expression of IL-1β, mainly observed in the 
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postsynaptic domain of the motor endplate, may be involved in proteolysis, since muscle 
exposed to IL-1β have less myogenic cells (Authier et al., 1999).  
 
Human myoblasts, in vitro, constitutively express IL-6. However, IL-1β and TNF-α release 
in muscle requires stimulation by TNF-α itself or interferon (De Rossi et al., 2000). Most 
research into the role of IL-6 in muscle has concerned the role of IL-6 during exercise. 
Although IL-6 is released by numerous other cells, during exercise the predominant source 
of IL-6 in plasma is muscle (Febbraio & Pedersen, 2002). An important function of IL-6 in 
muscle is to regulate glucose homeostasis, either by affecting glucose production by the 
liver, or regulating the uptake of glucose by the muscle (Febbraio & Pedersen, 2002).  
 
3.2 Cytokines during exercise 
 
Cytokines are released during muscle contraction regardless of the type, intensity or 
duration of the exercise. However, the type, intensity and duration of the exercise 
determine the degree and, to some extent, which cytokines are released. TNF-α has been 
detected after exhaustive endurance exercise. After a marathon run of 42.5km, plasma 
TNF-α was elevated. However, there was no increase in TNF-α gene expression in muscle 
(Ostrowski et al., 1998b). Another study showed no increase in circulating TNF-α after 
marathon running, but the ambient temperature during that marathon was about 7 ºC 
(Suzuki et al., 2000). It is likely that the increases in circulating TNF-α seen after marathon 
running arise from the combination of heat stress and exhaustive exercise leading to 
increased gut permeability, rather than as a result of TNF-α released from contracting 
muscle or leukocytes.  
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Since TNF-α impairs glucose uptake by the cell, it would be counter-adaptive to express or 
release TNF-α from muscle during exercise. Also, TNF-α does not appear in serum for up 
to 5 days after eccentric exercise or exercise that induces muscle damage (Toft et al., 2002). 
Although myocytes, when stimulated in vitro, are able to release and express TNF-α, TNF-
α is not expressed nor released in normal healthy muscle at rest or after exercise 
(Saghizadeh et al., 1996; Steensberg et al., 2002). It is possible though, that the method of 
measuring circulating TNF-α, in some of the studies, was not sensitive enough to detect 
small concentrations of TNF-α after eccentric exercise (Smith et al., 2000). Peterson and 
Pederson (2005) propose that a negative feedback mechanism, possibly IL-10 or IL-1ra, 
occurs in muscle to prevent the release of TNF-α. If this hypothesis is true, it would 
explain why TNF-α is not elevated after eccentric exercise but is increased in other 
autoimmune muscle diseases. One of the proposed mediators contributing to the negative-
feedback on TNF-α is IL-6. 
 
Interleukin-6, released downstream of TNF-α during inflammation, is released from 
muscle into the plasma, during and after isometric, concentric and eccentric contraction 
(Febbraio & Pedersen, 2002). Increases in plasma IL-6 concentrations are dependent on 
the duration and intensity of the exercise (Ostrowski et al., 1998a). IL-6 plays an important 
role in substrate utilization. It was initially thought that the release of IL-6 was related to 
the extent of muscle damage. However, the release of IL-6 is independent of muscle 
damage since there is no correlation between the creatine kinase concentrations and the IL-
6 plasma concentrations (Ostrowski et al., 1998a).  
 
Although TNF-α stimulates IL-6 production from monocytes and macrophages during 
fever and inflammation, monocytes do not contribute to the plasma IL-6 or TNF-α 
concentrations during prolonged exercise, but rather the circulating IL-6 emanates from 
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contracting muscle cells (Steensberg et al., 2000; Starkie et al., 2001). IL-6 most likely plays 
an endocrine function since it is released into the circulation, targeting the liver, leading to 
increased substrate availablitity. Also, IL-6 release and expression by glycogen-depleted 
muscle is significantly higher than that of glycogen-replete muscle (Steensberg et al., 2001; 
Steensberg et al., 2002), and it may act on the GLUT-1 transporter to increase glucose 
uptake into the cell (Steensberg et al., 2001). Therefore, unlike in fever and inflammation, 
there does not appear to be a clear link between TNF-α and IL-6 in exercising muscle, 
unless IL-6 acts as a negative feedback to TNF-α. 
 
Interleukin-8, like IL-6, plays a role in substrate utilization in skeletal muscle during 
exercise. IL-8 is produced by monocytes and macrophages and other tissues including 
skeletal muscle (Akerstrom et al., 2005). Plasma IL-8 concentration, after marathon 
running, increased by 2.5 times over that of pre-marathon values (Suzuki et al., 2000). 
However, in other studies there was no change in plasma IL-8 after a 3h treadmill run 
(Nieman et al., 2003). IL-8 expression in skeletal muscle is increased after exhaustive 
exercise where both concentric and eccentric muscle contraction are done, but an increase 
in muscle IL-8 also occurs with concentric exercise alone (Akerstrom et al., 2005). 
Therefore, IL-8 expression and release in muscle is induced by concentric muscle 
contraction and is influenced by glycogen availability (Chan et al., 2004).  
  
One cytokine not involved in glucose metabolism but more likely to be related to muscle 
injury is IL-1β (Chan et al., 2004). It is produced by unstimulated myogenic cells and 
induces disorganization of the actin cytoskeleton in vitro (Authier et al., 1999). IL-1β 
appears to be released most prominently in monocytes and myocytes after eccentric 
exercise. IL-1β is expressed in post-synaptic domain of motor-end plates in normal muscle 
and in myofibres showing myofibrillar breakdown in diseased muscle (Authier et al., 1999). 
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Lipopolysaccharide-stimulated mononuclear cells taken from subjects 24h after a downhill 
run had increased concentration of IL-1β and TNF-α (Cannon et al., 1991). This increase 
in IL-1β and TNF-α correlated to an increase in protein breakdown as evident by urinary 
3-methylhistadine (Cannon et al., 1991). Not only was IL-1β release increased in 
monocytes but muscle biopsy samples taken from subjects completing 45min of downhill 
running showed an increase in IL-1β immunostaining around the capillaries and along 
plasma membranes 45min after the exercise and 5 days after the exercise. No IL-1β 
staining was detected within the myocytes and no TNF-α was detected within or around 
the muscle at either time interval (Cannon et al., 1989; Fielding et al., 1993).  
 
In another study where muscle biopsies were taken in 23 healthy male subjects after leg 
exercises that induced voluntary muscle failure, IL-1β was increased in some subjects more 
than other subjects (Dennis et al., 2004). There was a correlation between the IL-1 
genotype and the amount of IL-1β expressed. If IL-1β does contribute to muscle pain, this 
finding may explain why certain people experience more muscle pain than others, even 
after taking the muscle strength and fitness into account. Although IL-1β concentration in 
muscle is increased after eccentric exercise, immediately after and 24h after a 42km 
marathon run, there was no significant change in myocyte IL-1β expression (Ostrowski et 
al., 1998b). Therefore, the IL-1β may be synthesized by residents cells other than myocytes. 
It appears that IL-1β may be released in muscle only during muscle damage and that it has 
a local function since, regardless of the type of exercise, circulating IL-1β does not appear 
to be elevated after any type of exercise, regardless of intensity or duration (Fielding et al., 
1993; Ostrowski et al., 1998b; Suzuki et al., 2000). Therefore, the main function of IL-1β in 
muscle is proteolysis and it may be a key mediator in muscle pain, but no studies have 
correlated muscle IL-1β concentration and the subject’s perceived pain. 
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Since some cytokines are pleiotropic, they may produce different effects depending on the 
type of muscle contraction, intensity and severity of the exercise. However, it does appear 
that IL-6 and IL-8 play a more prominent role in muscle metabolism, while IL-1β is 
involved in muscle degeneration. TNF-α release is inhibited in most instances including 
after both concentric and eccentric exercise and possibly even endurance exhaustive 
exercise. TNF-α is likely to be increased only in instances where homeostasis is disturbed 
or marked injury and inflammation occurs.  
 
3.3 Role of cytokines in muscle pain 
A primary problem in identifying the pro-inflammatory cytokines contributing to muscle 
pain, as mentioned in section 3.2, is that muscle releases and produces some of the same 
cytokines during normal muscle contraction. Since most muscle pains are associated with 
movement and muscle contraction, it is difficult to establish whether the pro-inflammatory 
cytokines released in the muscle and in the circulation contribute to normal muscle 
homeostasis or if they indeed contribute to the pain experienced. In order to investigate 
the contribution of pro-inflammatory cytokines to muscle pain, it is best then, to use 
experimental models that do not incorporate exercise, or to compare the concentration of 
cytokines in clinical disease states to those of normal healthy controls. In this section I have 
discussed the literature on the role that cytokines play in muscle pain, independent of 
exercise.  
 
Exogenous TNF-α injected into the gastrocnemius muscle of a rat produced a dose-
dependent reduction in force grip strength and a decrease in pressure threshold on the 
muscle (Schafers et al., 2003). The mechanical hyperalgesia was produced 6h after injection 
and lasted until 28h after injection, and the intensity of hyperalgesia was comparable to that 
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found after formalin was injected into the gastrocnemius muscle. There was no 
development of secondary hyperalgesia, as measured by pressure and heat applied to the 
contralateral paw, implying a local effect (Schafers et al., 2003). It is likely that TNF-α 
stimulated the release of other inflammatory mediators such as prostaglandin E2 and 
calcitonin-gene related peptide, which were found to be elevated in the muscle tissue 
(Schafers et al., 2003). Whether TNF-α stimulates the release of other cytokines was not 
investigated and would be worthy of further investigation. In a conflicting study, TNF-α 
intramuscular injection desensitized group IV afferents to pressure (Hoheisel et al., 2005). 
However, these measurements were taken within the first ten minutes of injection and it is 
possible that a different response may have been obtained 5h after injection when the 
hyperalgesia of the previous study was most apparent (Schafers et al., 2003).  
 
Even though TNF-α injected into muscle may produce hyperalgesia, it is not clear whether 
TNF-α is endogenously produced during muscle injury. Five hours after a freeze injury to 
rat muscle, another model used to induce muscle injury, TNF-α concentration in the 
muscle increases, peaking 24h after injury, with TNF-α concentrated in the invading 
inflammatory cells (Warren et al., 2002). Therefore, TNF-α may contribute towards muscle 
pain, but a freeze injury is a severe muscle injury and the release of TNF-α may be 
dependent on the extent of the muscle injury.  
 
Unlike TNF-α, IL-6 injected into muscle resulted in an increased response in two out of 
seven low-threshold mechanoreceptors, but not to high-threshold nociceptors (Hoheisel et 
al., 2005). Also, IL-6 serum concentration measured in patients with fibromyalgia was not 
different compared to that of age and gender matched controls (Wallace et al., 2001).  
Therefore, IL-6 may not play a role in clinical muscle pain, although only a handful of 
studies have looked at the role of IL-6 in muscle pain. 
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In the same group of patients diagnosed with fibromyalgia, in which IL-6 was not elevated, 
there was an elevation in serum IL-8 (Wallace et al., 2001). Although IL-8 plays a role in 
muscle homeostasis, it also is a chemokine. Since fibromyalgia includes other symptoms 
such as insomnia and fatigue, IL-8 may play a role in fibromyalgia other than that of the 
associated muscle pain. Little work has been done investigating the role of IL-8 in muscle 
pain and therefore may be worthy of future studies.  
 
Few studies have investigated the role that IL-1β may play in muscle pain. Muscle biopsies, 
from patients with various myopathies, showed an increased expression for both TNF-α 
and IL-β, with a more intense staining for TNF-α around muscle spindles. Also, IL-1β was 
found in the vascular walls and in some inflammatory cells located in the endomysium and 
perimysium (Mackiewicz et al., 2003). However, circulating IL-1β was not increased in 
patients with fibromyalgia compared to that of age and gender matched controls. As 
mentioned in section 3.2, IL-1β is increased in muscle in exercise-induced muscle injury, 
without an increase in plasma IL-1β. Therefore, if IL-1β was to play a role in clinical 
muscle pain, it is likely that there would be no increase in circulating IL-1β, but rather an 
increase in the muscle itself, or in the central nervous system. 
 
Although some studies have begun to investigate the role that cytokines play in animal 
models of muscle pain and in clinical muscle pain conditions, the field of research requires 
substantial progress before a full understanding and optimal treatment regimens are 
obtained. 
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Thesis aims 
 
Our understanding of inflammatory muscle pain has been based mainly either on studies 
using cutaneous pain models in animals or on human models where exercise induces pain. 
Although the mechanisms of inflammatory muscle pain are thought to be similar to those 
of cutaneous inflammatory pain, it is not known if the profile of mediator release indeed is 
similar. In Chapter 2 I wished to identify whether differences were apparent in cytokine 
profiles and hyperalgesia between inflamed hind paw tissue and another inflamed 
cutaneous tissue such as the rat tail. Many studies have investigated the pro-inflammatory 
cytokine release during inflammation and compared the concentrations measured to that of 
the behavioural response of the rats, yet few have investigated the temporal profile of the 
four prominent pro-inflammatory cytokines concurrently, and compared the cytokine 
response to both the behavioural response of the rats and to histological changes. 
Therefore, the aim of Chapter 2 was to fully characterize the inflammatory response to a 
carrageenan injection into cutaneous tissue. I found that the inflammatory process in the 
rat tail and the associated hyperalgesia were comparable to that of the hind paw. Because 
injection into the tail, unlike that in the paw, does not impair animal movement, 
carrageenan injection into the rat tail may be a useful model to investigate the relationship 
between inflammatory hyperalgesia and voluntary activity. 
 
Once I had investigated the pro-inflammatory cytokine cascade in a unique cutaneous 
tissue of the rat tail, and found comparable cytokine and behavioural changes to those 
found in the hind paw of rats, I wanted to identify if the responses in muscle tissue were 
different to that in cutaneous tissue. In Chapter 3 I set out to identify the pro-inflammatory 
cytokine concentrations, in both the muscle tissue and the plasma, after carrageenan 
injection into the gastrocnemius muscle of the rat. I also compared the concentrations of 
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cytokines to the behavioural response of the rats after applying noxious mechanical 
pressure to the inflamed muscle. In order to better understand the mechanism behind 
clinical inflammatory muscle pain, I needed to identify a model of inflammatory muscle 
pain that is independent of exercise. Since painless muscle contraction itself causes the 
local release of cytokines, a model of inflammatory muscle pain that releases cytokines in 
resting muscles may provide a better method to elucidate the cytokines that contribute to 
the hyperalgesia. In Chapter 3 I showed that cytokines are released after carrageenan 
injection into the muscle of rats and found that the cytokine release and hyperalgesia 
followed a different temporal profile to that found in cutaneous carrageenan-induced 
inflammation. 
 
Although carrageenan-induced muscle inflammation may provide answers to the 
mechanisms underlying muscle inflammation in animal models, we do not have a 
comparable model in humans and cannot inject carrageenan into humans. Possibly the best 
human model of inflammatory muscle hyperalgesia, where the variables can be controlled 
in a laboratory setting, is exercise-induced muscle pain or DOMS. Although our 
understanding of how pain arises from exercise-induced muscle damage is incomplete, the 
damage is thought to have an inflammatory component. If so, blocking some part in the 
inflammatory process should attenuate the muscle pain. At the time that I conducted this 
research, drugs were not available to block the release of any of the pro-inflammatory 
substances measured thus far in this thesis. Interleukin-1β and IL-6 both stimulate the 
release of cyclo-oxygenase, increasing the production of prostaglandins, so it also may be 
possible to attenuate muscle pain by blocking prostaglandin synthesis. Many studies have 
attempted to attenuate DOMS using non-selective COX-inhibitors, but the results are 
contradictory and tentative. Therefore, the aim of Chapter 4 was to inhibit the activity of 
COX-2, the COX isoform released during inflammation, after inducing delayed-onset 
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muscle soreness by downhill running of human volunteers. Although inflammation is 
thought to play a role in DOMS by leading to peripheral sensitization of the muscle 
nociceptors, it also is thought that central sensitization occurs. If so, a central-acting 
analgesic may alleviate the pain experienced in DOMS. Tramadol binds to mu-opioid 
receptors. It also prevents the reuptake of serotonin and adrenaline within the central 
nervous system, therefore stimulating the descending inhibitory pathway involved in 
analgesia. The second aim of Chapter 4 was to identify whether a central-acting analgesic 
was able to attenuate DOMS. 
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ABSTRACT 
 
We produced experimental inflammatory hyperalgesia by injecting carrageenan into the tail 
of Sprague-Dawley rats. We compared the rats’ voluntary running wheel activity following 
carrageenan injection into the tail to that after carrageenan injection into the hind paw, the 
conventional site of inflammation, to identify whether the site of inflammatory-induced 
hyperalgesia altered voluntary activity. We also measured voluntary running before and 
after injection of carrageenan or saline into the tail or hind paw, and in separate groups of 
rats we measured the nociceptive response and the associated pro-inflammatory cytokine 
profiles following a carrageenan injection into the tail. Female rats were injected 
intradermally with either 2mg carrageenan or saline into the dorsal surface of the tail. 
Withdrawal responses to noxious heat (49°C water), and punctate mechanical (electronic 
anaesthesiometer) challenges were recorded in 12 rats for three days before and 1h to 48h 
after injection. In a separate group of rats, interleukin (IL)-1β, IL-6, tumour necrosis factor-
alpha (TNF-α) and cytokine-induced neutrophil chemoattractant (CINC-1) concentrations 
were measured in plasma and tail tissue samples taken at the site of injection, 3h, 6h and 
24h after injections. Voluntary wheel running was reduced significantly following 
carrageenan injection into the hind paw compared to that after saline injection into the 
hind paw. Carrageenan injection into the tail did not result in significant reduction in wheel 
running compared to that after saline injection into the tail. Both thermal and mechanical 
hyperalgesia were present after carrageenan injection into the tail (P<0.01, ANOVA). The 
hyperalgesia at the site coincided with significant increases in TNF-α, IL-1β, IL-6 and 
CINC-1 tissue concentrations, peaking 6h after carrageenan injection (P<0.01, ANOVA). 
We conclude that carrageenan injection into the tail produces inflammatory hyperalgesia 
with underlying pro-inflammatory cytokine release, but does not affect voluntary running 
wheel activity in rats.  
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1. INTRODUCTION 
Inflammatory pain often has been investigated experimentally by injecting noxious agents 
such as carrageenan, complete Freund’s adjuvant and formalin into the hind paw of a rat 
(Vinegar et al., 1987; Hargreaves et al., 1988; Woolf et al., 1997; Bianchi et al., 2004) These 
studies have advanced substantially our understanding of the mechanisms of cutaneous 
inflammatory pain. However, pain in the cutaneous tissue of the hind paw affects the 
weight-bearing ability of the animals and disrupts their normal activities. Therefore, the 
hind paw model may not be suitable for use in studies that wish to investigate the effects of 
pain on exercise, or any other activities in rats.  
 
Clinically, exercise regimens are prescribed routinely to patients with various chronic pains 
(Sculco et al., 2001). However, there is no mechanistic evidence to support the notion that 
exercise positively alters pain perception. To investigate the therapeutic effects of exercise 
on pain it would be useful to identify an alternate site of inflammation, in a non-weight 
bearing site, that produces the same inflammatory response and behavioural response to 
that seen in the hind paw of the rat. Additionally, it is important to understand the 
interaction between activity and pain in nociceptive testing. Voluntary running, at least in 
rats, is known to alter the antinociceptive effects of opioids (Kanarek et al., 1998; D'Anci et 
al., 2000; Mathes & Kanarek, 2006). Rats engage in high noctural activity, even in small 
cages (Ottenweller et al., 1998), so patterns of activity may be important in some 
nociceptive tests.  
 
The tail of the rat, like the paw, is accessible to noxious thermal and mechanical challenges 
with the animal loosely restrained but not handled (Vidulich & Mitchell, 2000). The tail has 
a thick keratinised epithelium and is the site used conventionally for many other 
nociceptive assays, including the tail flick test (D'Amour & Smith, 1941), our reperfusion 
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hyperalgesia model (Gelgor et al., 1986), and incisional (Weber et al., 2005). We therefore 
investigated whether procedures developed to generate carrageenan-induced inflammation 
in the foot also could be used in cutaneous tissue of the tail. The first aim of our study was 
to compare the voluntary activity of rats following carrageenan injection into the hind paw 
to that after carrageenan injection into the tail 
 
We also investigated the inflammatory cytokine cascade, which contributes to the 
development and maintenance of hyperalgesia in cutaneous inflammation (Poole et al., 
1999a). Inflammatory mediators, like bradykinin, which are released from injured tissue, 
sensitize and directly stimulate nociceptors, and stimulate tumour necrosis factor alpha 
(TNF-α) release (Basbaum & Woolf, 1999). This TNF-α in turn, stimulates the release of 
interleukin-1beta (IL-1β) and interleukin-6 (IL-6). Interleukin-1β and IL-6 promote the 
induction of cycloxygenase enzymes, which convert arachidonic acid to prostaglandins that 
sensitize nociceptors. Tumour necrosis factor-alpha also stimulates the release of cytokine-
induced neutrophil chemoattractant (CINC-1) in rats or interleukin-8 (IL-8) in humans 
(Shibata et al., 2000). In addition to attracting inflammatory cells to the injured site, CINC-1 
stimulates the release of sympathetic amines (Poole et al., 1999a; Lorenzetti et al., 2002). 
Cytokines, like IL-1β, TNF-α and IL-6, contribute directly to the development of 
hyperalgesia by sensitizing peripheral nociceptors, decreasing the peripheral nociceptor 
threshold (Ferreira et al., 1988; Cunha et al., 1992; Lorenzetti et al., 2002). We therefore 
measured pro-inflammatory cytokine concentrations in tissue at the site of injection, and in 
the blood of rats to which we had given tail injections of carrageenan, to determine if a 
similar cytokine response occurred in the tail tissue to that found in the hind paw.  
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2. MATERIALS AND METHODS 
 
2.1 Animals 
For tests of voluntary running wheel activity, female Sprague-Dawley rats, weighing 200-
220g at the time of injection, were housed individually in cages, at an ambient temperature 
of 25-26°C, with attached running wheels. For the nociceptive testing, female Sprague-
Dawley rats, weighing 200-220g at the start of the experiment, were housed in groups of 
four per cage, and were allowed standard rat chow and tap water ad libitum. The rats were 
housed in a temperature-controlled environment at 21-22°C on a 12:12 hour light dark 
cycle (lights on at 07:00). A group of animals different to that which underwent 
behavioural nociceptive testing, randomly selected from the same breeding stock, was used 
to obtain blood and tissue samples and housed in the same experimental conditions. The 
experimental procedures were approved by the Animal Ethics Screening Committee of the 
University of the Witwatersrand, South Africa (2003/99/3 and 2004/73/3), and were 
conducted in accordance with the International Association for the Study of Pain 
requirements for research on animals (Zimmerman, 1983).  
 
2.2 Experimental procedures 
Carrageenan (lambda carrageenan, 2mg, Sigma-Aldrich, Johannesburg, South Africa) was 
suspended in 100µl sterile isotonic saline (0.9%) before injections. We injected 100µl of 
carrageenan solution or 100µl 0.9% saline into the dermis of the rat’s tail using a 0.5mm 
diameter needle, at the midpoint of the dorsal surface of the tail, adjacent to the vein. For 
the running wheel measurements, each rat received one injection at 17:00 so that the peak 
of the inflammation occurred in the dark phase of the 24h-day, when rats are most active. 
For the behavioural, cytokine and histological testing, each animal received one injection 
only, which was administered between 08:00 and 10:00.  
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2.3 Voluntary running wheel activity 
Each rat was placed individually in a cage with an attached running wheel (circumference 
of 1.06m). Each wheel was equipped with a magnet and a magnetic switch connected to a 
computer where voluntary running wheel activity, in five-minute intervals, was measured 
using a behavioural monitoring system (VitalView, Minimitter, Sunriver, OR, USA).  Rats 
with a voluntary daily running distance of at least 1 km, over 14 days, were selected for the 
study. Since day-time running is negligible, only night-time running distance was analyzed 
(19:00-07:00).  Running distance was determined from the number of wheel turns for the 
12-hour night-time interval. The total number of wheel turns per night was expressed as a 
percentage change from pre-injection (average of 5 nights) running distance. Voluntary 
activity was recorded for three nights after injection. Since voluntary activity is affected by 
oestrus cycle, we performed two vaginal lavages (100µl sterile saline) on each rat, at least 
three days apart. The live cell samples were analysed under a microscope and classified, 
using the system used by Montes and Luque (Montes & Luque, 1988) into the four phases 
of the oestrus cycle, namely oestrus, proestrus, metoestrus and dioestrus. The rats were 
divided randomly into four groups, each rats received either saline or carrageenan into 
either the hind paw or the tail (n=8-9 per group).  
 
2.4 Behavioural nociceptive measurements 
For behavioural measurements, the rats (n=12 per group) were placed in clear plastic 
restrainers that allowed free movement of the tail while limiting movement of the rest of 
the body. Rats were familiarized with the restrainers for two hours per day on three 
consecutive days before measurements started. Behavioural measurements were taken daily 
for 4d before injection, and 1h, 3h, 6h, 24h and 48h after injection. Withdrawal response 
latency to a noxious thermal challenge was assessed before the noxious mechanical 
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challenge was applied, to eliminate any risk of hyperalgesia developing as a result of the 
application of a noxious mechanical stimulus (Vidulich & Mitchell, 2000). 
  
2.4.1 Withdrawal response to a noxious thermal challenge 
The rat’s tail was immersed in a water bath controlled at 29 °C, to maintain a constant tail 
temperature, 30min before measurements and between measurements (Berge et al., 1988; 
Tjolsen et al., 1989). One of us (LL) measured the withdrawal response latency to a noxious 
thermal challenge following rapid immersion of the entire tail in an unstirred water bath 
controlled at 49 °C, as the time from submerging the tail in the water to the first 
coordinated response. The mean of three consecutive measurements, taken at one-minute 
intervals, was recorded. Any rat that did not respond within 30s had its tail removed from 
the water bath, to avoid tissue damage to the tail.  
 
2.4.2 Withdrawal response to a noxious mechanical challenge.  
We assessed withdrawal response threshold to a noxious mechanical pressure by applying 
punctate pressure, using an electronic von Frey anaesthesiometer (ITTC, Life Sciences, 
USA), at a consistently increasing rate, to the dorsal surface of the tail, at the site of 
injection. We recorded the minimum force (g) which elicited a brisk withdrawal or escape 
behaviour. A mean of three measurements at the injection site, and 30mm above the 
injection site, one minute apart, was recorded.  
 
2.5 Histology 
We injected an additional nine animals with 2mg carrageenan in 100µl saline at the 
midpoint of the dorsal surface of the tail. Three animals were killed, with intraperitoneal 
injection of sodium  pentobarbital (Euthanase, Kyron, Johannesburg, South Africa), at 3h, 
6h and 24h after injection and sections from the site of injection were removed and 
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processed for later histological analysis. A further three animals were killed 24h after 100µl 
saline injection, and tissue sections of the tail were removed for histological analysis as 
control tissue. Sections of tail tissue, including dermis and underlying fascia, tendon and 
muscle were fixed in 10% formalin and embedded in paraffin wax. Paraffin sections of all 
tissues were stained with haematoxylin and eosin and examined by light microscopy. 
Descriptive histological analysis of the sections was performed by one of us (BM), a 
pathologist, blinded to the treatment. 
 
2.6 Cytokine concentrations 
In separate groups of rats, under isofluorane anaesthesia (Safeline Pharmaceuticals, 
Johannesburg, South Africa), we collected blood and tail tissue 3h, 6h and 24h after 
injection of carrageenan or saline (n=6 per treatment group and time interval). Blood first 
was collected by cardiac puncture, into sterile tubes containing EDTA, and centrifuged at 2 
000rpm for 10min at 4°C. The plasma was stored at -70 °C until assayed. The rats then 
were killed by intracardiac injection of 1ml sodium pentobarbital (Euthanase, Kyron, 
Johannesburg, South Africa), and tail tissue from the site of injection was removed, 
weighed, frozen in liquid nitrogen and stored at -70 °C for cytokine analysis. Tissue 
samples were homogenised in phosphate buffered saline (PBS, pH = 7.4) containing 0.4M 
NaCl, 0.05% Tween-20, 0.5% bovine serum albumin, 0.1mM benzethonium chloride, 
10mM EDTA and 20KI/ml aprotinin. The homogenates were centrifuged at 12 000g for 
60 min at 4 °C. The supernatant was removed and analysed, as was the plasma, for IL-1β, 
IL-6, CINC-1 and TNF-α.  
 
2.7 Rat-specific ELISA for cytokines   
Cytokine concentrations were determined using an enzyme-linked immunosorbent assay 
(ELISA, National Institute of Biological Standards and Control, South Mimms, UK), as 
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previously described (Safieh-Garabedian et al., 1995). Microtitre plates were coated 
overnight with sheep anti-rat polyclonal antibody. 100µl standard recombinant rat cytokine, 
or sample, was added to each well and left overnight at 4 °C. Each sample was measured in 
duplicate. Sheep anti-rat biotinylated polyclonal antibodies were added at a 1:2000 dilution, 
and the sample incubated at room temperature (21-22 ºC) for 1h. Finally, 100µl of 
streptavidin-polyHRP (1:10000 dilution, Euroimmun, Cape Town, South Africa) was 
added to each well, at room temperature. After 30 min the plates were washed and the 
colour reagent o-phenylenediamine dihydrochloride (40µg, 100µl.well-1, Sigma-Aldrich, 
Johannesburg, South Africa) added. The reaction was terminated with H2SO4 (1M, 
150µl.well-1) and the optical density measured at 490nm. The results were expressed as 
pg.ml-1 for the plasma, and pg.mg-1 for tail tissue. TNF-α, IL-1β, IL-6 and CINC-1 
concentrations were measured with the appropriate sheep anti-rat polyclonal and 
biotinylated antibodies for each cytokine. The ELISA for IL-β detected both precursor and 
mature IL-1β but did not cross-react with IL-1α or IL-1ra. The ELISAs for TNF-α, IL-6 
and CINC-1 did not cross react with each other or with the ELISA for IL-1β. As a result 
of the high concentrations of cytokines in some samples from sites of inflammation, the 
samples required large dilutions. The detection limit of each assay, which allowed for the 
dilution factor of the sample, varied between tissue and plasma samples, and between 
treatment groups, and is reported with the results of the assay. 
 
2.8 Data analysis 
All data are expressed as mean ± SD. Voluntary activity, response latency to noxious heat 
and response threshold to noxious pressure were expressed as the percentage change from 
pre-injection value for each rat. Voluntary activity, behavioural responses and cytokine 
concentrations were compared between animals receiving carrageenan and saline by means 
of two-way analysis of variance (main effects, intervention and time) with Student 
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Newman-Keuls (SNK) post hoc test when appropriate. When cytokine concentrations were 
undetectable, samples were assigned the detection limit of the assay. Statistical significance 
was taken at P< 0.05.  
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3. RESULTS 
3.1 Voluntary running wheel activity 
The rats’ voluntary running wheel activity, averaged over four days before injection, was 
significantly higher in the oestrus phase (11232 ± 5228counts/12h) compared to proestrus 
(5149 ± 5662 counts/12h), metoestrus (4960 ± 7166counts/12h) and dioestrus (5632 
±4767 counts/12h, P<0.001, F3,132=9.36). Therefore, the pre-injection running wheel data 
excluded running activity when the rats were in oestrus, and injections were not given to 
rats in the oestrus phase. Figure 1 shows the percentage change in running wheel activity 
from pre-injection running, following saline or carrageenan injection into the hind paw or 
the tail. The percentage change in running wheel activity following an injection into the 
hind paw showed a significant difference between rats injected with carrageenan compared 
to those injected with saline (P<0.001, F1,45=40.90) on the night of injection and one night 
after injection (P<0.05, F1,45=4.80), but there was no significant interaction (P=0.48, 
F2,45=0.74). The percentage change in running wheel activity following an injection into the 
tail showed no significant difference between rats injected with carrageenan or saline 
(P=0.09, F1,45=3.08), at any time (P=0.19, F1,45=1.70) and there was no significant  
interaction (P=0.69, F2,45=0.37).  
 
3.2 Behavioural nociceptive responses  
Figure 2 shows the response latency to noxious heat and the response threshold to noxious 
pressure at the site of injection. The response latency to noxious heat showed a significant 
agent effect (P<0.01, F1,22=13.47) and time effect (P<0.001, F4,88=6.65), but no significant 
interaction (P=0.08, F4,88=2.16). Pressure threshold showed an agent effect (P<0.01, 
F1,22=9.04), but no significant time effect (P=0.67, F4,88=0.59) or interaction (P=0.06, 
F4,88=2.31).  
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3.3 Histology  
The animals that received a saline injection showed a trivial influx of inflammatory cells at 
the site of injection, and then in only one out of the three animals (Fig. 3D). Samples taken 
at the site of injection, three hours after carrageenan injection showed mild inflammatory 
infiltrate in the subcutaneous tissue, as evident by the presence of neutrophils, 
lymphocytes, plasma cells, and occasional eosinophils (Fig. 3A). Samples taken six hours 
after carrageenan injection (Fig. 3B) showed moderate to severe inflammatory cell infiltrate 
in the dermis and subcutaneous tissue. The severe inflammation was evident by the 
presence of neutrophils, eosinophils, lymphocytes, and plasma cells, but no macrophages. 
Twenty-four hours after carrageenan injection, the tail tissue at the site of carrageenan 
injection (Fig. 3C) showed a moderate inflammatory cell infiltrate containing mainly 
lymphocytes and neutrophils with associated oedema at both sites. No fibrosis or 
granulomas appeared within 24h of the carrageenan injection. 
 
3.4 Cytokine concentration  
TNF-α: Six hours, but not 3h or 24h, after carrageenan injection, TNF-α concentration in 
the tail tissue was elevated significantly compared to the concentration in animals injected 
with saline (P<0.001, SNK, Fig. 4), at the site of injection. Plasma TNF-α concentration, 
after carrageenan or saline injection, was below the detection limit of the assay at all times.  
 
IL-1β: Six hours after carrageenan injection, IL-1β tail tissue concentration was elevated 
significantly compared to the concentration found in animals injected with saline (P<0.001, 
SNK, Fig. 4), and had dropped, but still was elevated significantly 24h after injection 
(P<0.01, SNK, Fig. 4). IL-1β tail tissue concentration of animals injected with carrageenan 
was significantly higher at 6h compared to the concentration found 3h after carrageenan 
injection (P<0.001, SNK), and that found 24h after carrageenan injection (P<0.001, SNK). 
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Tail IL-1β concentration still was elevated significantly 24h after carrageenan injection 
compared to 3h after carrageenan injection (P<0.001, SNK, Fig. 4). Following carrageenan 
injection into the tail, there was no significant increase in plasma IL-1β (P=0.42, ANOVA) 
concentration compared to that of the animals injected with saline, and concentrations 
were below the detection limit of the assay (7.1pg.ml-1, data not shown) at all times.  
 
IL-6: Six hours after carrageenan injection, IL-6 concentration at the site of injection was 
elevated significantly compared to the concentration found in animals injected with saline 
(P<0.001, SNK, Fig. 4), and had dropped markedly, but still was elevated significantly 
(P<0.05, SNK, Fig. 4) 24h after injection. IL-6 tail tissue concentration of animals injected 
with carrageenan was significantly higher at 6h compared to the concentration found 3h 
after carrageenan injection (P<0.001, SNK). Following a carrageenan injection into the tail, 
there was no significant increase in plasma IL-6 concentration (P=0.56, ANOVA) 
compared to the animals injected with saline, and in most cases IL-6 concentration was 
below detection limit of the assay (6.6pg.ml-1, data not shown).  
 
CINC-1: Figure 5 shows the CINC-1 concentration in both tail tissue and plasma after 
saline or carrageenan injection into the tail. There was a significant elevation in tail CINC-1 
concentration, at the site of injection, after carrageenan injection compared to that after 
saline injection, 3h (P<0.0001, SNK, Fig. 5) and more so 6h (P<0.001, SNK) after 
injection. CINC-1 concentration in the tail of animals injected with carrageenan had 
dropped to the same as that following saline injection by 24h after injection. The plasma 
CINC-1 concentration after carrageenan injection was significantly higher than that of 
saline-injected animals (P<0.01, SNK, Fig. 5), 6h after injection, but was not elevated either 
3h or 24h after injection.  
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4. DISCUSSION 
We determined that the tail is a suitable site, comparable to the hind paw, for producing 
inflammatory-induced hyperalgesia. We assessed the behavioural responses of rats to two 
modalities of noxious challenge, applied to the site of an intradermal injection of the 
irritant carrageenan into the tail, and also investigated the concomitant changes in histology 
and in tail tissue and plasma cytokine concentrations. The change in withdrawal response 
to both noxious heat and noxious pressure showed the animals to be hyperalgesic after 
carrageenan injection into the tail. The peak in hyperalgesia, at the site of the carrageenan 
injection, which occurred 6h after carrageenan injection, coincided with moderate to severe 
inflammatory cell infiltration. Our results also showed substantial increase in pro-
inflammatory cytokine concentrations at the site of injection with the concentrations of all 
four pro-inflammatory cytokines, TNF-α, IL-1β, IL-6 and CINC-1, also peaking 6h after 
injection. However, only CINC-1 concentration was elevated at the site of injection at 3h 
after injection, by which time the hyperalgesia was established. Twenty-four hours after 
carrageenan injection tail TNF-α and CINC-1 concentrations were no longer significantly 
elevated; the interleukins still were elevated, but their concentrations had dropped 
significantly below the 6h peak. We found no difference in running wheel activity between 
rats injected with carrageenan into the tail compared to rats injected with saline into the tail. 
In contrast, we found a significant reduction in voluntary running wheel activity in rats 
injected with carrageenan into the hind paw compared to that of rats injected with saline 
into the hind paw. 
 
No previous studies have investigated the effects of hyperalgesia on voluntary activity or 
exercise in experimental animals. Although a previous study found a reduction reduction in 
cage activity in rats injected intramuscularly into the thigh with turpentine, an hyperalgesic 
agent, the researchers did not measure the presence of hyperalgesia (Saha et al., 2005). A 
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reduction in voluntary running wheel activity occurs during  infection and fever, which are 
often associated with inflammation (Katafuchi et al., 2003; Harden et al., 2006). Our finding 
that an injection of carrageenan into the hind paw, but not the tail, reduces voluntary 
running wheel activity reveals the impoprtance of the site of inflammation in altering 
activity. Injection into the tail, which results in comparable cytokine and behavioural 
responses after injection into the hind paw, therefore offers a useful alternative site for 
producing hyperalgesia without altered voluntary activity.   
 
Regardless of the site of carrageenan-induced inflammation, TNF-α and IL-1β 
concentrations increase early, with peak IL-1β concentration, according to previous 
reports, occurring before a peak in TNF-α concentration (Woolf et al., 1997; Loram et al., 
2007). In our hands, peak TNF-α concentration coincided with the elevation in other 
cytokines, but we believe that our initial sampling intervals may have been too long to 
reveal accurately the temporal sequence of TNF-α, IL-1β, IL-6 and CINC-1 secretion. In 
addition, although we produced significant thermal hyperalgesia and mechanical 
hyperalgesia, our statistical analysis could not resolve when hyperalgesia first appeared, or 
disappeared. We also could not analyse the resolution of cytokine profiles following 
carrageenan injection, because the concentrations of some cytokines in tail tissue still were 
elevated at 24h, when we took our last tissue samples.  
      
Numerous studies investigating inflammatory hyperalgesia have used carrageenan as an 
inducer of acute inflammation by injecting carrageenan into the hind paw of a rat (Winter et 
al., 1962; Vinegar et al., 1987; Hargreaves et al., 1988). The responses to noxious heat and 
noxious pressure, which we observed, are comparable to those described after carrageenan 
injection into a rat’s hind paw, with peak hyperalgesia occurring within a few hours and 
resolving by 24h (Winter et al., 1962; Vinegar et al., 1987; Hargreaves et al., 1988; Tabo et al., 
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1998; Yamamoto et al., 1998). Similar behavioural changes to noxious heat and noxious 
pressure, with the same temporal pattern, were evident after a carrageenan injection, in 
spite of the tail having thick keratinised skin, and the hind paw having thin glabrous tissue.  
 
Our hyperalgesia to both noxious heat and noxious pressure reached its peak 6h after 
injection, coinciding with the peak inflammatory cell infiltrate at the site of injection. In our 
study, comparable to a previous study injecting carrageenan into the hind paw (Vinegar et 
al., 1987), neutrophils, lymphocytes and plasma cells, with occasional eosinophils, invaded 
the site by 3h after carrageenan injection into the rat’s tail. Although we found oedema 
only at 24h after injection, following injection of carrageenan into hind paw Vinegar et al. 
(1987) found oedema from 1h after injection, and lasting for 48h, perhaps indicating a 
greater susceptibility of the hind paw to oedema during inflammation.  
 
TNF-α, which is produced by inflammatory cells and other tissue cells such as 
keratinocytes (Zhang et al., 1995), produces hyperalgesia to noxious pressure within 1h of 
injection, peaking 3-5h after injection, and resolving within 24h  (Cunha et al., 1992; Woolf 
et al., 1997). Also, neutralising TNF-α attenuated thermal hyperalgesia at 3h and prevented 
mechanical hyperalgesia occurring 3h to 6h after carrageenan injection (Cunha et al., 2000). 
In the rat tail, like in the rat hind paw, we found coincidence in the time course of peak 
local TNF-α concentration and hyperalgesia (Woolf et al., 1997) where thermal hyperalgesia 
appeared before elevated TNF-α concentration could be detected in the hyperalgesic tissue, 
and mechanical hyperalgesia persisted after TNF-α concentration had returned to normal. 
 
As with TNF-α, IL-1β and IL-6 concentrations in tail tissue were not elevated before or 6h 
after carrageenan injection, but remained elevated 24h after injection. IL-1β, a well-
described activator of nociceptors, (Ferreira et al., 1988), when injected into the hind paw 
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produces mechanical hyperalgesia in a dose and time-dependent manner (Cunha et al., 
2000; Cunha et al., 2005), but the hyperalgesia resolves within 24h (Ferreira et al., 1988; 
Cunha et al., 2000; Cunha et al., 2005). Elevation of local IL-1β and IL-6 concentrations are 
likely to play a role in sensitizing peripheral nociceptors following a carrageenan injection, 
though, just as with TNF-α, they are unlikely to be the sole cytokines responsible for 
sensitizing the nociceptors, particularly because hyperalgesia was established before a 
detectable elevation of IL-1β or IL-6 concentration occurred, in tail tissue. 
 
Of the cytokines we measured, the time course of CINC-1 best matched the onset of 
hyperalgesia. The chemokine, CINC-1, stimulates the release of sympathetic amines 
involved in hyperalgesia (Lorenzetti et al., 2002), and attracts neutrophils to the injured area 
(Shibata et al., 2000). CINC-1 has been implicated not only in peripheral nociceptor 
sensitization but also in central nervous system activation during inflammation, thereby 
contributing to mechanical hyperalgesia (Yamamoto et al., 1998). In our study, tissue 
CINC-1 concentration had increased by 3h, and both tissue and plasma concentration 
peaked 6h after carrageenan injection. Recombinant rat CINC-1 injected into the hind paw 
of rats produced a mechanical hyperalgesia similar to the hyperalgesia found after 
carrageenan injection (Lorenzetti et al., 2002). In our study, CINC-1 was the only cytokine 
with elevated plasma concentration after tail carrageenan injection, but we do not know 
whether that circulating CINC-1 had any functional role.  
 
In conclusion, we have identified a site of carrageenan-induced inflammation that results in 
hyperalgesia with concurrent changes in local tissue histology and cytokine production of 
the thick keratinized tissue of the tail comparable to those characterized for the well 
established models of inflammation in the rat hind paw. We also have developed a method 
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for generating hyperalgesia in the rat tail without decreasing voluntary running activity, as 
occurs following inflammation in the hind paw of rats.  
 67 
FIGURE LEGENDS 
Figure 1 Change in voluntary running wheel activity after 100µl saline () or 2mg/100µl 
carrageenan () into the tail or the hind paw (n=8-9 per group). Values are expressed as a 
percentage change from pre-injection values for each rat (mean ± SD). Injections were 
given at 17:00 and running activity was recorded as the sum of the wheels counts from 
19:00 to 07:00 on the night of injection and for 2 nights after injection. Pre-injection 
running wheel counts were 5795±4139counts/12h. There was a significant reduction in the 
voluntary activity of rats injected with carrageenan into the hind paw compared to rats 
injected with saline into the hind paw (**P<0.001, *P<0.05). Carrageenan injection into the 
tail did not significantly affect running wheel activity compared to rats injected with saline 
into the tail, at any time after injection (P=0.09).  
 
Figure 2 Change in withdrawal response latency to noxious heat, and change in response 
threshold to noxious pressure at the site of injection after 100µl saline () or 2mg/100µl 
carrageenan () into the tail 1h, 3h, 6h, 24h and 48h (n=12 per group). Values are 
expressed as a percentage change from pre-injection values for each rat (mean ± SD). Pre-
injection withdrawal latency to noxious heat was 5.9±1.3s and pre-injection to noxious 
pressure threshold was 181±54g. Carrageenan injection induced significant thermal 
(P<0.01, ANOVA) and mechanical hyperalgesia (P<0.01, ANOVA) at the site of injection 
compared to animals injected with saline.  
 
Figure 3 Histological changes in the superficial tissue of a rat’s tail, at the site of injection, 
3h (A), 6h (B) and 24h (C) after 2mg/100µl carrageenan injection into the dorsal surface of 
the tail. (D) shows histology, at the injection site, of a rat’s tail 24h after saline injection. All 
sections were stained with haemotoxylin and eosin and photographed at 100x 
magnification with epidermis orientated to the top. Arrows indicate: (A), the presence of 
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neutrophils, lymphocytes, plasma cells, and occasional eosinophils; (B), the presence of 
neutrophils, eosinophils, lymphocytes, and plasma cells; and (C), a moderate inflammatory 
cell infiltrate containing mainly lymphocytes and neutrophils with associated oedema .  
 
Figure 4 TNF-α, IL-1β and IL-6 concentration (mean ± SD, n=6 per group) in the tail 
tissue at the site of intradermal injection of carrageenan (2mg/100ul saline,) or saline (, 
100µl). There was a significant difference in TNF-α concentration in the tail tissue after 
carrageenan injection compared to saline injection 6h after injection, but not at 3h or 24h 
after injection. IL-1β concentration in tail tissue was significantly higher following 
carrageenan injection than following saline injection, 6h and 24h after injection. IL-1β 
concentration following carrageenan injection was higher 6h than 24h after injection. 
Tissue IL-6 concentration was significantly higher following carrageenan injection than 
following saline injection, 6h and 24h after injection. IL-6 concentration following 
carrageenan injection was higher at 6h than at 24h following injection.  ---- indicates level 
of detection of assay. * indicates P<0.05 and *** indicates P<0.001 between saline and 
carrageenan injected animals at the same time interval. # # #  indicates P<0.001 between time 
intervals after carrageenan injection. 
 
Figure 5 CINC-1 concentration (mean ± SD, n=6 per group) in the plasma and 
homogenized tail tissue at the site of injection after intradermal injection of carrageenan 
(2mg/100ul saline, ) or saline (100µl, ). Tissue CINC-1 concentration was significantly 
higher 3h following carrageenan injection, and even more so 6h afterwards, than following 
saline injection. Plasma CINC-1 concentration was significantly higher 6h after carrageenan 
injection into the tail than after saline injection into the tail. ---- indicates level of detection 
of assay. * indicates P<0.05 and ** indicates P<0.01 between saline and carrageenan 
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injected animals at the same time interval. #  indicates P<0.05,  # #  indicates P<0.01 and # # # 
indicates P<0.001 between time intervals after carrageenan injection.  
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The main roles of cytokines during cutaneous inflammation have been elucidated. 
However, the exact mechanism of how cytokines contribute to hyperalgesia, in 
particular muscle hyperalgesia is less clear. For example, whether cytokine receptors are 
present on muscle nociceptors, and if the same cytokines that sensitize cutaneous 
nociceptors are able to sensitize muscle nociceptors has not been determined. If the 
pro-inflammatory cytokines are able to induce muscle hyperalgesia, it is yet to be 
established whether the cytokines produce an intensity and temporal profile of 
hyperalgesia in muscle comparable to that found in inflamed cutaneous tissue. Finally, 
it is not clear whether other chemical mediators known to sensitize cutaneous 
nociceptors, such as prostaglandin, produce a similar effect in muscle. In this thesis I 
have addressed some of the issues raised above in order to further understand the 
mechanism of inflammatory muscle pain, in particular the role chemical mediators play 
in peripheral sensitization of muscle nociceptors during inflammation. The results 
obtained from the studies I undertook are summarized in this chapter. 
 
5.1 Inflammatory hyperalgesia, cytokines and histology 
The hind paw of rats is the conventional site used to investigate inflammatory 
hyperalgesia (Vinegar et al., 1987; Hargreaves et al., 1988). Despite extensive studies 
investigating the mechanisms of inflammatory hyperalgesia (Winter et al., 1962; Vinegar 
et al., 1987; Cunha et al., 1991; Cunha et al., 1992; Safieh-Garabedian et al., 1995; Cunha 
et al., 2000; Lorenzetti et al., 2002), no studies have investigated concurrent histological 
changes and changes in hind paw and plasma pro-inflammatory cytokines. The 
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glabrous epidermis and underlying fat pad of the hind paw are different to that of 
other cutaneous tissue within the body in that the glabrous tissue is thicker and hair 
follicles are absent. I therefore also investigated the effects of injecting carrageenan, an 
inflammatory agent, into a tissue different to the cutaneous tissue of the hind paw, 
namely the keratinized tissue of the rat tail, and measured the behavioural response to a 
noxious pressure and noxious heat (Chapter 2). I found that an injection of 
carrageenan into the rat tail induces both mechanical and thermal hyperalgesia, with 
thermal hyperalgesia induced within three hours and mechanical hyperalgesia within six 
hours of injection. Both the thermal and mechanical hyperalgesia resolved 24h after 
injection. The behavioural responses following injection of carrageenan into the rat tail 
(Chapter 2) are comparable to those found in other studies, including my own study 
(Chapter 3), where carrageenan was injected into the hind paw (Vinegar et al., 1987; 
Hargreaves et al., 1988) 
Since inflammatory hyperalgesia can be induced by carrageenan injection into the rat 
tail, I then measured the cytokine changes in both the plasma and the tail tissue, and 
the histological changes (Chapter 2), to identify whether the temporal profile of the 
hyperalgesia is comparable to that of the histological changes and the cytokine 
concentrations. I found that the peak in hyperalgesia, measured at the site of the 
carrageenan injection, coincided with moderate to severe inflammatory cell infiltration. 
My results also showed a substantial increase in pro-inflammatory cytokine 
concentrations at the site of injection with the concentrations of all four pro-
inflammatory cytokines, TNF-α, IL-1β, IL-6 and CINC-1, peaking at the same time as 
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that of the hyperalgesia and the cell infiltration. Therefore, at any site of cutaneous 
inflammation, the hyperalgesia, histology and cytokine release are likely to be similar.  
Although it has been well established that cytokines contribute to inflammatory 
hyperalgesia, the exact mechanism is yet to be determined. TNF-α, IL-1β and IL-6 are 
able to sensitize nociceptors, but is not clear how this sensitization is attained, or 
whether cytokine receptors are present on nociceptors. It is possible that pro-
inflammatory cytokines stimulate the release of other mediators, such as neurotrophic 
growth factor (NGF), substance P and prostaglandins, all of which sensitize 
nociceptors (Baldwin Lanier, 2003). IL-1β and IL-6 both stimulate the release of cyclo-
oxygenase, a rate-limiting enzyme in the synthesis of prostaglandins. Prostaglandins 
sensitize cutaneous nociceptors and IL-1β- and IL-6-induced hyperalgesia is attenuated 
by a COX-inhibitor, indomethacin (Cunha et al., 1992). Therefore, IL-1β and IL-6 may 
not directly sensitize nociceptors, but rather sensitize nociceptors by stimulating the 
release of prostaglandins. Nonetheless, IL-6 and IL-1β do contribute directly or 
indirectly to cutaneous inflammatory hyperalgesia. 
My findings do not resolve whether these cytokines directly contribute to the 
hyperalgesia induced. However, my findings are in agreement with previous studies 
(Winter et al., 1962; Vinegar et al., 1987; Cunha et al., 1992; Safieh-Garabedian et al., 
1995; Lorenzetti et al., 2002), the results of which infer that the inflammatory cell 
infiltration and the pro-inflammatory cytokines released during inflammation, 
regardless of the cutaneous site injected, contribute to the inflammatory hyperalgesia 
induced by carrageenan injection. I believe that both TNF-α and IL-1β play an 
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important role in inflammatory hyperalgesia in cutaneous tissue, but through 
stimulating the release of other mediators such as prostaglandins, NGF and substance 
P (Safieh-Garabedian et al., 1995; Woolf et al., 1997). Further work that is able to 
identify receptor molecules found on nociceptors and the receptor activity is required 
to confirm any direct role that pro-inflammatory cytokines play in inflammatory 
hyperalgesia. 
The role that one of the pro-inflammatory mediators, the chemokine, CINC-1, plays in 
inflammatory hyperalgesia has received little attention. It is involved in sympathetically-
mediated pain and inflammatory hyperalgesia (Lorenzetti et al., 2002). CINC-1 may 
play a more important role in central sensitization which follows peripheral activation 
of nociceptors by other inflammatory mediators (Yamamoto et al., 1998). However, my 
findings show a relationship between the hyperalgesia and the CINC-1 concentration 
in the inflamed tissue. It seems that CINC-1 may play a role locally and also at a site 
remote from the site of inflammation, such as within the central nervous system. The 
function of CINC-1 at a more remote site would explain the increased plasma CINC-1 
concentration. I propose that one of the roles that CINC-1 may have at the site of 
inflammation, during inflammatory hyperalgesia, is to increase the infiltration of 
inflammatory cells which subsequently release cytokines to the area of inflammation 
and contribute to neurogenic inflammation. This theory would explain why atenolol 
and propanolol, adrenergic-receptor antagonists, attenuated CINC-1 induced 
hyperalgesia (Cunha et al., 1991). It would also explain why following an injection of 
carrageenan, in my rats CINC-1 concentrations increased early, attracting neutrophils 
and increasing infiltration of further inflammatory mediators. The function of CINC-1 
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during inflammatory hyperalgesia needs further research, especially to identify CINC-1 
receptors and their location. 
5.2 Inflammatory hyperalgesia in muscle 
In addition to studying inflammatory hyperalgesia in cutaneous tissue, I also 
investigated inflammatory hyperalgesia in muscle and compared the hyperalgesia to 
that of inflamed cutaneous tissue. Muscle pain is different to cutaneous pain in quality, 
pattern of pain and duration, but the mechanisms underlying these differences are yet 
to be determined. Carrageenan has been used previously to induce muscle 
inflammation, and in particular inflammatory muscle hyperalgesia (Berberich et al., 
1988; Radhakrishnan et al., 2003). I induced muscle hyperalgesia in rats, similar to that 
found in previous studies (Kehl et al., 2000), by injecting carrageenan into the muscle. 
Unlike Radhakrishnan et al (2003) who were able to produce bilateral secondary 
hyperalgesia in the hind paw after unilateral injection of carrageenan into the 
gastrocnemius muscle, I found no secondary hyperalgesia in the contralateral limb.  
Although muscle inflammatory hyperalgesia has been induced previously, no studies 
have measured the cytokine changes that occur with the inflammation. My findings 
show that cytokines are elevated following injection of carrageenan into the muscle, 
but that the temporal patterns of the change in IL-1β and IL-6 are different to those 
found after cutaneous inflammation, in the hind paw, and different to the temporal 
pattern of muscle hyperalgesia. Also, at no time interval that I measured was muscle 
TNF-α concentration elevated above that of muscle injected with saline. 
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There are conflicting results regarding the effect that TNF-α has on muscle pain. 
Exogenous TNF-α, injected into muscle induces mechanical hyperalgesia (Schafers et 
al., 2003). TNF-α, however, also desensitizes muscle nociceptors (Hoheisel et al., 2005), 
but does so within 20min following TNF-α injection, with mechanical hyperalgesia still 
evident 6h to 28h after injection. Therefore, TNF-α may initially desensitize muscle 
nociceptors, and later sensitize muscle nociceptors, resulting in hyperalgesia.  
Although TNF-α injected into muscle induces hyperalgesia (Schafers et al., 2003), 
muscle TNF-α concentrations are not elevated following eccentric exercise (Malm et 
al., 2000; Toft et al., 2002) or, as my study shows, after carrageenan injection (Chapter 
3). TNF-α is a key inflammatory mediator in cutaneous tissue but it does not appear to 
be important in muscle inflammation. TNF-α has catabolic effects in muscle such that 
increased concentrations of TNF-α in muscle results in proteolysis and muscle wasting  
(Goodman, 1991; Li & Reid, 2001), as evident in patients with sepsis, rheumatoid 
arthritis and human immunodeficiency virus (Rall et al., 1996; Moldawer & Sattler, 
1998; Coletti et al., 2005). However, it still remains controversial as to whether TNF-α 
alone is able to result in cachectic effects in experimental conditions in vivo (Flores et 
al., 1989; Michie et al., 1989; Mullen et al., 1990; Goodman, 1991; García-Martínez et al., 
1993; Peterson et al., 2006).  
TNF-α also plays a role in insulin resistance by impairing glucose storage and glucose 
uptake, as evident in patients with diabetes mellitus (Saghizadeh et al., 1996; Zhang et 
al., 2000). TNF-α may also play a role in sarcopenia associated with aging (Dirks & 
Leeuwenburgh, 2006). Although TNF-α is produced in resting muscle (Saghizadeh et 
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al., 1996), the release of TNF-α into normal muscle appears to be suppressed by IL-6 
(Starkie et al., 2003). In a study conducted in our laboratory on healthy male volunteers, 
where mild skeletal muscle injuries were induced by eccentric leg presses, TNF-α 
concentrations in muscle are not appear elevated (Rice TL, Chantler I, Loram LC, 
unpublished data). However, in extreme injuries, such as a freeze injury in rats (Warren 
et al., 2002), and rheumatoid arthritis in humans (Flagg et al., 2005), muscle TNF-α 
concentration is elevated. Therefore, under normal homeostatic conditions the release 
of TNF-α in muscle is suppressed, but if the skeletal muscle injury is more severe or 
the muscle homeostasis is disturbed, TNF-α concentration in muscle is elevated.  
Unlike TNF-α, IL-1β and IL-6 concentrations are elevated following muscle injury, but 
their release is different in muscle inflammation compared to in cutaneous 
inflammation, with the release of IL-1β and IL-6 being delayed in muscle 
inflammation. No work has investigated the role of IL-1β in muscle pain, but it is a 
potent sensitizer of nociceptors in cutaneous tissue (Ferreira et al., 1988). It still is not 
clear whether IL-1β is able to sensitize nociceptors directly by acting on IL-1 receptors, 
but it does stimulate the release of cyclo-oxygenase enzymes, which synthesize 
prostaglandins.  
If IL-1β sustains inflammatory hyperalgesia in muscle, it would be worthwhile 
investigating the rat’s behavioural response following an intramuscular injection of 
carrageenan and the administration of an inhibitor of IL-1β, such as a caspase-1 
inhibitor, at the site of inflammation and within the spinal cord.  In addition, further 
investigations should attempt to identify the presence of prostaglandins and NGF in 
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the muscle, and possibly block their effects. Nonetheless, my study investigating the 
cytokine profile following an injection of carrageenan into the muscle is a useful model 
to investigate the mechanisms of inflammatory muscle pain. Targeting possible key 
mediators in this model of inflammatory muscle pain may illuminate some novel 
therapeutic targets in treating clinical muscle pain.  
5.3 Clinical muscle pain  
Animals models used to mimic clinical conditions allow us to measure variables 
invasively and manipulate conditions in a manner that is difficult to do ethically in 
human studies. However, if we are to transfer conclusions drawn from animal-based 
experiments to human pathology, it is best to confirm the results obtained using a 
human experimental model. Therefore, I investigated muscle pain in humans using an 
experimental model where pain can be induced in the laboratory under controlled 
conditions, but the pain induced also is experienced during daily activities, particularly 
unaccustomed exercise (Chapter 4).  DOMS is the most appropriate model for 
inflammatory pain as DOMS is produced in part from muscle inflammation and micro 
trauma. Much is understood of DOMS regarding the muscle injury and the associated 
symptoms, but a few key questions are unanswered. Firstly, what causes the pain 
associated with the micro trauma to the muscle after unaccustomed exercise and, 
secondly, why is there a delay in the pain experienced?  
In the study reported in chapter 4, I attempted to identify possible mechanisms behind 
the pain associated with DOMS assuming that inflammation played a role. IL-1β is 
elevated during muscle inflammation (Chapter 2), and is elevated following eccentric 
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muscle contractions (Cannon et al., 1989; Fielding et al., 1993). IL-1β stimulates the 
release of prostaglandins, via cyclo-oxygenase stimulation, which sensitize nociceptors. 
Therefore, COX-inhibitors should attenuate DOMS. Previous studies have attempted 
to investigate which COX inhibitors attenuate DOMS, but with little success (Baldwin 
Lanier, 2003). Trappe et al. found that 400mg ibuprofen, a non-selective COX 
inhibitor, with low activity for COX-2, administered after the exercise failed to 
decrease soreness in the affected muscle (Trappe et al., 2002). DOMS also was 
unaltered by  another non-selective COX inhibitor, naproxen, and by a putative COX-
3 inhibitor, paracetamol (acetaminophen), administered after the exercise (Lecomte et 
al., 1998; Barlas et al., 2000a). I showed that DOMS induced after exercise was not 
attenuated by the selective COX-2 inhibitor, rofecoxib (Chapter 4). COX-inhibitors 
therefore fail to relieve DOMS, irrespective of what iso-enzyme they target. Therefore, 
at the time that DOMS is evident, it is not being sustained by newly synthesized 
prostaglandin. Thus, I confirm that, though prostaglandin may be synthesized in the 
affected muscle during DOMS (Trappe et al., 2001), agents that inhibit its synthesis, at 
doses effective for other pains, do not affect the intensity of the DOMS, when 
administered after the exercise. 
 
It is possible that DOMS has a unique mechanism of pain distinct from other muscle 
pains, or, as is the case in cutaneous tissue, IL-1β stimulates the release of  mediators 
not acting through prostaglandins, such as NGF and substance P (Safieh-Garabedian et 
al., 1995; Woolf et al., 1997), which may be important mediators in muscle pain.   
Although previous studies have found an elevation in prostaglandins when muscle 
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soreness was apparent 24h after eccentric exercise (Trappe et al., 2001; Tegeder et al., 
2002), during carrageenan-induced muscle inflammation there were only some muscle 
nociceptors desensitized by acetylsalicylic acid treatment. Therefore, although 
prostaglandins are produced in muscle, only some muscle nociceptors are sensitized by 
prostaglandins (Diehl et al., 1988).  
 
Therefore, IL-1β may be important in inflammatory muscle pain by sensitizing muscle 
nociceptors either via prostaglandin synthesis or via other mediators such as NGF. 
Regardless of the mechanism of nociceptor sensitization, IL-1β does not initiate the 
hyperalgesia. In Chapter 3, my results show that the inflammatory hyperalgesia in the 
muscle developed before the IL-1β concentration in the muscle was elevated. 
However, it is possible that IL-1β may sustain the inflammatory muscle hyperalgesia 
once it has been established.  
It is possible that peripheral sensitization, via prostaglandin or other mediators may not 
be a key player in muscle pain, but that the key player is central sensitization. Central 
sensitization, the increased excitability of neurones in pain pathways in the dorsal horn 
of the spinal cord, occurs with longer lasting effects in muscle pain than in cutaneous 
pain (Wall & Woolf, 1984). Initially, central neurones are activated by nociceptive input 
from the periphery. If the input is sustained, molecular changes within the spinal cord 
occur, and central sensitization results (Woolf, 2004). Injecting hypertonic saline into a 
muscle produces a short-lasting muscle pain, while injecting hypertonic saline into a 
muscle that has DOMS does not produce pain in excess of that in a muscle that does 
not have DOMS (Weerakkody et al., 2001). In addition, in the same study, applying a 
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vibratory stimulus over the affected muscle increased muscle soreness following 
DOMS, but a vibratory stimulus did not induce muscle soreness in unexercised 
muscle. The implication of these findings is that the peripheral nociceptors, activated 
by the rapid change in sodium concentration after hypertonic saline injection (Graven-
Nielsen et al., 1997b), are not sensitized during DOMS, as evident by the lack of 
increased pain following a hypertonic saline injection. However, it is likely that central 
sensitization, rather than peripheral sensitization, is a key player in DOMS, and 
possibly all muscle pain.  
 
Tramadol decreases the impact of central sensitization by attenuating pain transmission 
through activating of opioid receptors and inhibiting noradrenaline and serotonin 
reuptake in the brain and spinal cord, therefore targeting the descending inhibitory 
pathways (Oliva et al., 2002). However, in my study, tramadol like codeine (60mg), 
another opioid,  had no effect on pressure pain tolerance or intrinsic pain in the muscle 
during DOMS (Barlas et al., 2000a). However morphine administered intravenously 
produced a significant attenuation of the muscle pain during DOMS (Tegeder et al., 
2003). Also, morphine-6-glucuronide (M6G), a morphine metabolite unable to 
penetrate the blood brain barrier, administered in a two hour intravenous infusion 
attenuated DOMS effectively (Tegeder et al., 2003). Morphine administered to rats 
after eccentric muscle contractions led to suppression of c-Fos activation in the dorsal 
horn of the spinal cord leading Taguchi et al. (2005) to infer that there is some spinal 
neuronal activation occurring in DOMS, but not necessarily nociceptor activation. 
Opioid therapy, such as levorphanol, attenuates inflammatory muscle hyperalgesia in 
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rats and clinical muscle pain,  such as fibromyalgia (Bengtsson et al., 1989; Sorensen et 
al., 1997; Kehl et al., 2000). Therefore, clarity is required as to whether opioids are 
effective in treating muscle pain, in particular DOMS. It is likely that effectively 
treating muscle pain requires larger doses of opioids than conventionally prescribed for 
other pains. In addition, agents targeting central rather than peripheral mechanisms 
may be more effective in treating the complex polymodal mechanism of DOMS and 
possibly clinical muscle pain (Woolf & Mannion, 1999).  
 
DOMS and clinical muscle pain such as whiplash and myofascial pain, are likely to 
differ, in mechanisms underlying the pain and in resultant muscle function. DOMS 
induced by unaccustomed exercise results in pain for no more than five days with a 
concomitant loss in muscle strength (Proske & Morgan, 2001). However, once the 
muscle soreness of DOMS has subsided there is muscle hypertrophy and improved 
muscle function (Proske & Morgan, 2001). Similarly clinical muscle pain, such as 
myofascial pain and fibromyalgia, results in muscle pain with a concomitant decrease in 
muscle function (Zedka et al., 1999). In contrast though, clinical muscle pain, regardless 
of whether the pain subsides or becomes chronic, results in muscle atrophy (Friden & 
Lieber, 2001). During DOMS, and possibly clinical muscle pain too, muscle strength 
impairment may be caused by impaired proprioception. However, no change or 
damage in the muscle spindles themselves has been identified during DOMS. 
Therefore, it is likely that there is a change in signal from the muscle spindle, or to the 
muscle spindle, relating to the effort required to produce a contraction, and resulting in 
instability of the muscle (Proske, 2005).  
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If muscle spindles are not damaged during DOMS, large fibre mechanoreceptors in 
muscle spindles may have nociceptive properties at a high threshold, which are 
activated during muscle injury or after excessive load. During muscle injury, the muscle 
spindles may become sensitized, so that muscle spindle activation, such as during 
muscle contraction or passive stretch, results in pain being perceived (Weerakkody et 
al., 2001). Applying a vibratory stimulus (6Hz) to the skin overlying a muscle, and 
activating large fibre mechanoreceptors decreases muscle pain induced by hypertonic 
saline. However, after DOMS has been induced, the muscle becomes more painful 
when applying the vibratory stimulus, indicating that group I large diameter fibres from 
muscle spindles may play a role in DOMS (Weerakkody et al., 2001; Weerakkody et al., 
2003). The involvement of muscle spindles during muscle pain supports the concept of 
a predominant central mechanism and a complex polymodal mechanism underlying 
muscle pain.  
In conclusion, I have demonstrated that the cytokine release during inflammatory pain 
is the same in different types of cutaneous tissue, namely hind paw tissue with the 
underlying fat pad and the thick keratinised tissue of the rat tail. I also have 
demonstrated that the cytokine release during inflammatory pain in muscle is different 
to that of inflammatory pain in cutaneous tissue. I have shown that, in cutaneous 
tissue, the cytokine release in the inflamed tissue coincides with the presence of the 
inflammatory cells, and the resultant hyperalgesia. However, in muscle inflammation, 
the cytokine release does not coincide with the hyperalgesia, with a delayed release of 
IL-1β and IL-6, and no increase in muscle TNF-α. Therefore, IL-1β and IL-6 may play 
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a role in sustaining the hyperalgesia and TNF-α may play little role in the inflammatory 
hyperalgesia induced. And finally, a complex polymodal mechanism likely underlies 
muscle pain since COX-inhibitors and a central-acting analgesic do not attenuate the 
muscle pain.  
Future research should include investigations into the central mechanisms of muscle 
pain and therapeutic agents to treat muscle pain are more likely to be successful if they 
target changes within the spinal cord rather than within the muscle itself. A study also 
should be directed at investigating the rat’s behavioural response following inhibition 
of IL-1β and CINC-1 at the site of muscle inflammation, in the circulation and within 
the spinal cord. Blocking the action of IL-1β and CINC-1 at all three sites would 
enable us to identify whether these two cytokines indeed are key mediators in 
inflammatory muscle hyperalgesia, and if so, where they play the greatest role. Should 
they play a role in carrageenan-induced inflammatory muscle hyperalgesia, then 
blocking the action of IL-1β and IL-8 in DOMS would be worth investigating. Not 
only blocking the action of IL-1β following carrageenan-induced muscle inflammation, 
but also blocking the action of NGF and prostaglandins should be investigated. Once 
the key pro-inflammatory mediators have been identified in inflammatory muscle pain, 
then these mediators should be measured in clinical muscle pain conditions such as 
myofascial pain, lower back pain and whiplash. Lastly, the mechanism by which these 
key pro-inflammatory mediators produce hyperalgesia should be tested, for example, 
by locating the appropriate receptors and determining how the mediators sensitize 
muscle nociceptors. There is much research still to be done to fully understand the 
underlying mechanisms of inflammatory muscle pain, requiring animal-based 
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experiments and human models of muscle pain followed by translational research into 
clinical muscle pain conditions.   
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